Immunization Protocol for Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine

As of September 16, 2021, the Pfizer-BioNTech COMIRNATY® vaccine is no longer under an Interim Order and has been officially authorized for use in Canada by Health Canada under Food and Drug Regulations. It was previously authorized for use in Canada under the Interim Order on December 9, 2020 for adults 18 years of age and older, and on May 5, 2021 for adolescents 12-17 years of age.

The change in name reflected in this protocol from Pfizer-BioNTech to Pfizer-BioNTech COMIRNATY® is a name change only. While this protocol includes updates to various sections including eligibility, handling and administration of the vaccine, there is no change to the vaccine formulation itself.

NOTE: The Moderna SPIKEVAX® COVID-19 vaccine is also in use in Nunavut. While both are mRNA vaccines, there are key differences between the Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® vaccines with respect to requirements for dilution/reconstitution, storage/transport, and temperature considerations. Please also be advised that a different formulation of BioNTech COVID-19 vaccine exists for ages 5-11 with a separate protocol from the one presented here.

Purpose	To provide information and guidance for the COVID-19 Immunization Program in Nunavut.
Objective	To reduce severe illness and death related to COVID-19 infection while also minimizing adverse societal impacts from COVID-19 and the pandemic response.
Indication	Active immunization against coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus in individuals aged 12 years of age and older.[1] Data on the efficacy of the Pfizer-BioNTech COMIRNATY® COVID-19 vaccine against emerging variants of concern is evolving.[2]
Eligibility	Individuals aged 12 years of age and older without contraindications to the vaccine.
Product	Pfizer BioNTech COMIRNATY®COVID-19 Vaccine (BNT162b2-mRNA SARS-CoV-2 vaccine).
Vaccine type	30 mcg of SARS-CoV-2 spike protein mRNA (for more information see references). Note: mRNA vaccines are not live vaccines and cannot cause infection in the host. mRNA vaccines also cannot alter a person's DNA.[2]
Vaccine components	*Medicinal ingre*dients: messenger ribonucleic acid (mRNA) *Non-medicinal ingredients*: ALC-0315 - ((4-hydroxybutyl) azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), ALC-0159 - 2-[(polyethylene glycol)- 2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3- phosphocholine, cholesterol, dibasic sodium phosphate dihydrate, monobasic potassium phosphate, potassium chloride, sodium chloride, sucrose, water for injection.
Formats available	Multiple-dose vials (up to 6 doses) preservative-free frozen suspension. Dilution is required.[1] Pfizer-BioNTech COMIRNATY® COVID-19 multiple dose vials have purple caps which distinguishes them from other formulations and manufacturers. After dilution each vial contains up to 6 doses of 0.3 mL using low-dead volume syringes and/or needles; only five doses may be available if a standard syringe and

	needle are used. The packaging on the vial indicates 5 doses are available but it is acceptable to withdraw 6 doses from a single vial.
Manufacturer	Pfizer-BioNTech COVID-19 Vaccine BioNTech Manufacturing GmbH An der Goldgrube 12 Mainz, Rhineland-Palatinate, Germany 55131
Thawing Prior to Dilution	Record the time removed from the freezer on the Pfizer *Mandatory Vial Tracking Form.* Prior to dilution minimize exposure to room light and avoid exposure to sunlight and ultraviolet light. **Prior to Dilution:** The Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine multiple dose vial contains a volume of 0.45 mL, supplied as a frozen suspension that does not contain preservative. Vials can be stored ultra-frozen (-80°C to -60 °C) until expiry date printed on the label provided cold chain is maintained. Vials can be stored frozen (-25 °C to -15 °C) for 14 days. Thaw vial(s) of COMIRNATY® before use either by: 1. Allowing vial(s) to thaw in the refrigerator (2°C to 8°C). A carton of vials may take up to 3 hours to thaw, and thawed vials can be stored in the refrigerator for up to 1 month (31 days). 2. Allowing vial(s) to sit at room temperature (up to 25°C) for 30 minutes. Using either thawing method, vials must reach room temperature before dilution and must be diluted within 2 hours of exposure to room temperature. Before dilution, invert vaccine vial gently 10 times. Do not shake. Inspect the liquid in the vial prior to dilution. The liquid is a white to off-white suspension and may contain white to off-white opaque amorphous particles. Do not use if liquid is discoloured or if other particles are observed.
Dilution	Obtain sterile 0.9% Sodium Chloride Injection, USP. Use only this as the diluent. This diluent is not packaged with the vaccine and will be provided separately. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent. Using aseptic technique, withdraw 1.8mL of 0.9% Sodium Chloride Injection, USP into a transfer syringe (21-gauge or narrower needle). Cleanse the vaccine vial stopper with a single-use antiseptic swab. Add 1.8mL of 0.9% Sodium Chloride Injection, USP into the vaccine vial.

	Equalize vial pressure before removing the needle from the vial by withdrawing 1.8mL air into the empty diluent syringe. Gently invert the vial containing COMIRNATY® 10 times to mix. Again, do not shake. Inspect the vaccine in the vial. Record the date and time of dilution on the vial label and on the Pfizer *Mandatory Vial Tracking Form.* Store between 2°C to 25°C. Discard any unused vaccine 6 hours after dilution. After dilution, one vial contains 6 doses of 0.3 mL. Vial labels and cartons may state that after dilution, a vial contains 5 doses of 0.3 mL. The information in this protocol regarding the number of doses per vial after dilution supersedes the number of doses stated on the vial labels and cartons. It will often be possible to obtain 6 doses from one vial.
Preparation of Individual 0.3mL Doses/Reconstitution	Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab and withdraw 0.3mL of COMIRNATY®, preferentially using low dead-volume syringes and/or needles. Each dose must contain 0.3mL of vaccine. If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3mL, discard the vial and any excess volume. Administer immediately, and no later than 6 hours after dilution.
Administration	**This vaccine has special storage and handling requirements. It should be transported frozen (typically ultra-frozen at -80 °C to -60 °C but in certain circumstances frozen at -25 °C to -15 °C) to remain stable. Follow the storage, thawing, and handling instructions in this protocol and from the COVID-19 Vaccine Transport Protocol in Appendix E carefully to ensure the vaccine will be effective.** **<u>Do not administer the vaccine</u> if the storage and handling guidance above has not been followed.** **Please see Appendix 2 for further guidance.** It is often helpful to use low-dead-volume syringes and/or needles. Irrespective of the type of syringe or needle: • Each dose must contain 0.3 mL of vaccine. • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. • Do not pool excess vaccine from multiple vials. • Administer immediately, and no later than 6 hours after dilution. Visually inspect each dose in the dosing syringe prior to administration. The diluted vaccine will be an off-white suspension. During the visual inspection:

	• verify the final dosing volume of 0.3 mL. • confirm there are no particulates and that no discolouration is observed. • do not administer if vaccine is discoloured or contains particulate matter. Administer Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine intramuscularly in the deltoid muscle. Do not inject the vaccine intravascularly, subcutaneously or intradermally.
Dose series	**Pfizer-BioNTech COMIRNATY® COVID-19 vaccine is administered intramuscularly after dilution as a series of two doses (0.3 mL each) 8 weeks apart.** The interval between dose 1 and dose 2 (8 weeks) has been revised based on emerging evidence regarding improved protection when extended beyond the currently authorized intervals. This guidance supersedes the dose interval recommended in the product monograph. The minimum interval is 19 days. The extended interval is 16 weeks (up to four months). If an individual is given a dose of mRNA vaccine outside of these parameters, an incident report should be filed on Meditech and the Regional Communicable Disease Coordinator (RCDC) should be consulted for additional dosing guidance. Canada's National Advisory Committee on Immunizations (NACI) has recommended that an additional dose of an authorized mRNA vaccine be provided as part of the primary series to moderately or severely immunocompromised (see section of protocol on additional dose for immunocompromised).[2] **NACI has also recommended that a booster dose of an authorized mRNA vaccine be provided following completion of the primary series (see Booster Dose section of protocol below).**[2]
Additional dose for immunocompromised	NACI has recommended that an additional dose of an authorized mRNA COVID-19 vaccine be provided as part of the *primary series* to moderately or severely immunocompromised individuals. A primary vaccine series is considered to be the number of vaccine doses needed to develop a complete and robust immune response. As immunocompromised individuals may have a reduced immune response to COVID-19 vaccines, an additional dose provides another opportunity for these individuals to develop a better immune response, completing their primary series.[2] Nunavut is adopting this NACI recommendation for its COVID-19 immunization programs. An additional full dose for immunocompromised individuals should be administered a minimum of 4 weeks after the second dose is given. Eligibility criteria for additional dose for immunocompromised patients: 1. Aged 12 years and older, having received 2 previous doses of mRNA COVID-19 vaccines.

	2. Meet the moderate to severely immunocompromised criteria. An individual will have one of the following (requires verification by clinicians authorized to diagnose and manage medical conditions): a. Active treatment for solid tumour or hematologic malignancies; b. Receipt of solid-organ transplant and taking immunosuppressive therapy; c. Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (with 2 years of transplantation or taking immunosuppression therapy); d. Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome); e. Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome; f. Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20, and CD22), high-dose systemic corticosteroids (refer to the Canadian Immunization Guide for suggested definition of high-dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. Please note: other jurisdictions may have a slightly different list of medical conditions to qualify an individual for an additional dose. 2. Meeting the minimal dosing interval requirement (at least 28 days) after receiving a 1 or 2-dose complete primary series.
Booster Dose	Waning immunity over time and efficacy of vaccines against variants of interest and variants of concerns are two factors that have been examined in the context of booster doses. Current NACI recommendations include a booster dose of a COVID-19 vaccine after the primary vaccine series is complete. For all Nunavummiut ages 12 and up who have received a primary COVID-19 vaccine series (with a homologous or heterologous schedule using mRNA or viral vector vaccines) a booster dose of an authorized mRNA COVID-19 vaccine (Pfizer-BioNTech COMIRNATY ® or Moderna SPIKEVAX®) should be offered a minimum of 6 months after completion of the primary series. Either Pfizer-BioNTech COMIRNATY ® or Moderna SPIKEVAX® can be used as a booster dose, regardless of which mRNA vaccine was used in the primary series. **The recommended booster dose for Pfizer-BioNTech COMIRNATY ® is 0.3mL for all recipients (full dose). This differs from Moderna SPIKEVAX® booster dose guidance where NACI recommends a half dose (0.25mL) for the general population.** This dose should be offered at an interval of at least six months after the primary series has been completed. Informed consent for a booster dose should include discussion about what is known and unknown about the risks and benefits, including the off-label status of NACI's recommendation. Please reach out to your RCDC if you have any questions about this guidance.

Vaccine interchangeability	NACI recommends that, if readily available, the **same** mRNA COVID-19 vaccine product should be offered for the subsequent dose in a primary vaccine series started with an mRNA COVID-19 vaccine. However, when the same mRNA COVID-19 vaccine product is not readily available, or is unknown, another mRNA COVID-19 vaccine product recommended for use in that age group can be considered interchangeable and should be offered to complete the vaccine series. The previous dose **should** be counted, and the series need not be restarted. [2] For mixed COVID-19 vaccine schedules, the minimum interval between doses should be based on the minimum interval of the product used for the first dose (e.g., Pfizer-BioNTech COVID-19 vaccine should be offered a minimum of 28 days after AstraZeneca COVID-19 vaccine).[2] Please contact your RCDC with any questions regarding vaccine interchangeability.
Contraindications	Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine is only authorized for use in people aged 12 years and older. Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine is contraindicated in individuals who are hypersensitive to the active substance or to any ingredient in the formulation or packaging of this specific vaccine.[1] Rare anaphylactic reactions have been reported following immunization with mRNA COVID-19 vaccines. One Pfizer-BioNTech COMIRNATY® vaccine component that has been identified as potentially resulting in a rare allergic reaction is polyethylene glycol (PEG). [2] If the patient has a history of myocarditis or pericarditis secondary to receipt of a COVID-19 vaccine, or a history of severe allergic reaction (e.g., anaphylaxis) after previous administration of a COVID-19 vaccine consult the Office of the Chief Public Health Officer (CPHO) for guidance before administering any subsequent dose of a COVID-19 vaccine.
Precautions and additional notes	***Anaphylaxis*:** Please see anaphylaxis section below for additional information on follow-up needed if anaphylaxis is suspected related to COVID-19 vaccination. As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of this vaccine. Vaccine recipients should be kept under observation for at least 15 minutes after immunization. Individuals with proven anaphylaxis to injectable therapy not related to a component of authorized COVID-19 vaccines (e.g. intramuscular, intravenous, or subcutaneous vaccines or therapies) may be routinely vaccinated – **an extended period of observation post-vaccination of 30 minutes should be provided**.[2] Individuals with suspected but unproven allergy to a vaccine component (e.g., PEG) may be routinely vaccinated and do not need a specific assessment regarding this suspected allergy - **an extended period of observation post-vaccination of 30 minutes should be provided.** [2]

Individuals with a history of allergy not related to a component of authorized COVID-19 vaccines or other injectable therapy (e.g., foods, oral drugs, insect venom or environmental allergens) can receive COVID-19 vaccines without any special precautions. **Individuals should be observed for a minimum of 15 minutes following vaccination**.[2]

Myocarditis and pericarditis: Very rare cases of myocarditis and pericarditis following vaccination with Pfizer-BioNTech COMIRNATY® COVID-19 vaccine have been reported during post-authorization use. These cases occurred more commonly after the second dose and in adolescents and young adults. Typically, the onset of symptoms has been within a few days following receipt of Pfizer-BioNTech COMIRNATY® COVID-19 vaccine. Available short-term follow-up data suggest that the symptoms resolve in most individuals, but information on long-term sequelae is lacking. The decision to administer the Pfizer-BioNTech COMIRNATY®COVID-19 vaccine to an individual with a history of myocarditis or pericarditis should consider the individual's clinical circumstances and the decision on further COVID-19 vaccines should be at the discretion of the Office of the CPHO. Cardiology consultation for management and follow-up should also be considered.[1]

Health care professionals are advised to consider the possibility of myocarditis and/or pericarditis in their differential diagnosis if individuals present with chest pain, shortness of breath, palpitations or other signs and symptoms of myocarditis and/or pericarditis following immunization with a COVID-19 vaccine. This could allow for early diagnosis and treatment.

***Acute illness*:** Consideration should be given to postponing immunization in persons with severe febrile illness or severe acute infection. Persons with moderate or severe acute illness should be vaccinated as soon as the acute illness has improved.

Vaccination of individuals who may be currently infected with SARS-CoV-2 is not known to have a detrimental effect on the illness. However, vaccination should be deferred in symptomatic individuals with confirmed or suspected SARS-CoV-2 infection, or those with respiratory symptoms, to avoid attributing any complications resulting from SARS-CoV-2 infection to vaccine-related AEFI and to minimize the risk of COVID-19 transmission at an immunization clinic/venue.[2]

***Hematologic-Bleeding*:** In individuals with bleeding disorders, the condition should be managed prior to immunization to minimize the risk of bleeding. Individuals receiving long-term anticoagulation are not considered to be at higher risk of bleeding complications following immunization and may be safely immunized without discontinuation of their anticoagulation therapy.[2]

Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration.[1]

	***Immune*:** Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the vaccine. They should still wear a mask as advised and practice a higher level of precautions until a significant proportion of their community has been immunized. Refer to guidance contained in *Additional dose for immunocompromised* section of protocol. ***Syncope*:** Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.
Administration of other vaccines, drugs, or biological products	**COVID-19 vaccines may be given at the same time as, or any time before or after, other vaccines, including live, non-live, adjuvanted or unadjuvanted vaccines.** Vaccines administered during the same visit should be administered at different injection sites. As with other vaccines, when possible, administration on the same day is preferred to vaccines being given within a few days of each other. Studies looking at the simultaneous administration of COVID-19 vaccines with other vaccines are underway and ongoing. NACI will continue to monitor the evolving evidence and will update recommendations as needed.[2] There is a theoretical risk that Pfizer-BioNTech COMIRNATY®COVID-19 vaccine may temporarily affect cell-mediated immunity, resulting in false-negative TST or IGRA test results. If tuberculin skin testing or an IGRA test is required, it should be administered and read before immunization or delayed for at least 4 weeks afterwards. Vaccination may take place at any time after all steps of tuberculin skin testing have been completed.[2] However, in cases where an opportunity to perform the TST or IGRA test might be missed, **the testing should not be delayed since these are theoretical considerations.** In this situation, re-testing, at least 4 weeks post immunization, of individuals with negative results for whom there is high suspicion of TB infection may be prudent to avoid missing cases due to potentially false-negative results. [2] Please refer to additional guidance provided by the Nunavut Tuberculosis Program. COVID-19 vaccines should not be given simultaneously with monoclonal antibodies or convalescent plasma – expert opinion should be sought on a case-by-case basis.[2]
Special Populations	***Individuals previously infected with SARS-CoV-2*:** People with SARS-CoV-2 infection can be vaccinated once they are no longer infectious and no longer have acute symptoms of COVID-19. NACI recommends previously infected individuals may receive a complete series of a COVID-19 vaccine. The optimal timing of vaccination after infection is not certain. Although it is known that re-infection is not common in the first 6 months after infection, the circulations of variants of concern may increase the risk of re-infection.[2]

	Individuals who have an autoimmune condition: *(*See above section ***Additional dose for immunocompromised*****).** People who are immunocompromised and people with autoimmune disease should be vaccinated with COVID-19 vaccines (unless otherwise contraindicated). As for all individuals, mRNA vaccines are the preferred option because of their higher efficacy and because they do not carry a risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Ideally, the COVID-19 vaccine series should be completed 2 weeks before starting immunosuppressive therapy or when immunosuppressive therapy is the lowest but can be given when needed. This ensures that COVID-19 protection is provided sooner. The immune response may be lower in those who are immunosuppressed. These individuals should continue to follow public health recommendations on preventing infection with SARS-CoV-2 (such as wearing a mask, physical distancing, and hand hygiene) even if they have been vaccinated. Vaccination of their close contacts will also help protect them. [2] ***Individuals who are pregnant or breastfeeding:*** People who are pregnant and breastfeeding should be vaccinated with COVID-19 vaccines (unless otherwise contraindicated). As for all individuals, mRNA vaccines are the preferred option because of their higher efficacy and because they do not carry a risk of VITT. Emerging evidence suggests that COVID-19 mRNA vaccination during pregnancy is also immunogenic and results in comparable antibody titres to those generated in non-pregnant women. Maternal IgG humoral response to mRNA COVID-19 vaccines transfers across the placenta to the fetus, leading to a significant and potentially protective, antibody titre in the neonatal bloodstream one week after the second dose. Observational studies consistently show that both anti-spike IgG and IgA are present in breastmilk for at least 6 weeks after maternal vaccination with mRNA vaccines.2
Post-vaccination counselling	Prophylactic oral analgesics or antipyretics (e.g., acetaminophen or ibuprofen) should not be routinely used before or at the time of vaccination, but their use is not a contraindication to vaccination. Oral analgesics or antipyretics may be considered for the management of vaccine side effects (e.g., pain or fever, respectively), if they occur after vaccination.[2] The After Care Sheet should be given to clients following vaccination.
Vaccine Supply and Distribution	Review section on vaccine ordering in the Policy and Procedure section of the Nunavut Drug Formulary. Follow vaccine vial inventory, tracking, and reporting processes. Wastage is to be documented for punctured and unpunctured vials separately. Questions or concerns re: vaccine supply and distribution should be forwarded to the Regional Pharmacies.
Storage and transport of frozen vials prior to use	Cartons of Pfizer-BioNTech BioNTech COMIRNATY® COVID-19 Vaccine multiple dose vials are shipped from southern Canada in thermal containers with dry ice (i.e. at ultra-frozen or -80°C to -60 °C conditions).

	Once received, remove the vial cartons immediately from the thermal container and preferably store in an ultra-low temperature freezer between -80°C to -60°C (-112°F to -76°F) until the expiry date printed on the label. Vials may also be stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks. **Vials must be kept frozen and protected from light, in the original cartons, until ready to use. Vials stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks may be returned one time to the recommended storage condition of -80°C to -60°C (-112°F to -76°F). Total cumulative time the vials are stored at -25°C to -15°C (-13°F to 5°F) should be tracked and should not exceed 2 weeks.** If an ultra-low temperature freezer is not available, the thermal container in which the Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine arrives may be used as temporary storage when consistently re-filled to the top of the container with dry ice. Refer to the re-icing guidelines packed in the original thermal container for instructions regarding the use of the thermal container for temporary storage. The thermal container maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage of the vials between -96°C to -60°C (-141°F to -76°F) is not considered an excursion from the recommended storage condition. ***Transportation of Frozen Vials*** If local redistribution is needed and full cartons containing vials cannot be transported at -90°C to -60°C (-130°F to -76°F), vials may be transported at -25°C to -15°C (-13°F to 5°F). Any hours used for transport at -25°C to -15°C (-13°F to 5°F) count against the 2-week limit for storage at -25°C to -15°C (-13°F to 5°F). Frozen vials transported at -25°C to -15°C (-13°F to 5°F) may be returned one time to the recommended storage condition of -80°C to - 60°C (-112°F to -76°F). Once received, the vaccine should be stored at temperatures of -25°C to -15°C unless otherwise advised by pharmacy and protected from light.
Storage of refrigerated, unpunctured and undiluted vials	Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 1 month (31 days) prior to first use. Prior to dilution vials can be stored for no more than 2 hours at room temperature. **Vials must reach room temperature before dilution. Please see guidance above.**
Storage of Punctured and diluted vials	After dilution, store vials between 2°C to 25°C (35°F to 77°F) and use within 6 hours from the time of dilution. Any vaccine remaining in vials must be discarded after 6 hours. After dilution, the vaccine vials can be handled in room light conditions.
Consent	Consent forms must be reviewed and signed prior to vaccination. Clients with capacity to consent (ie: 18+ and mature minors) will review and sign consent forms at time of vaccination. Clients without capacity to consent (ie: developmental delay, under 12 years of age) will require a parent or legal guardian to provide consent. (For more information: Appendix C Orientation to Obtaining Consent for Administration of COVID19 Vaccines).

Anaphylaxis	Review the principles of the emergency management of anaphylaxis in the Nunavut Immunization Manual Section 3 (3.7) including checking contents of the two anaphylaxis kits. Further information can be found in: Anaphylaxis: Initial Management in Non-Hospital Settings, in the Canadian Immunization Guide. NACI recommends that in individuals with a history of a severe, immediate (≤4h following vaccination) allergic reaction (e.g., anaphylaxis) after previous administration of an mRNA COVID-19 vaccine, administration of a subsequent dose in the series when indicated may be offered with the same vaccine or the same mRNA platform if a risk assessment deems that the benefits outweigh the potential risks for the individual and if informed consent is provided. The risk of a severe immediate allergic reaction after re-immunization appears to be low and no long-term morbidity has been associated with re-vaccination. **For any further immunization after anaphylaxis to a previous dose of an mRNA COVID-19 vaccine, consultation with an allergist AND guidance and approval from the Office of the CPHO must first be obtained. Please reach out to your RCDC.** If re-vaccinated, vaccine administration should be done in a controlled setting with expertise and equipment to manage anaphylaxis. Individuals should be observed for at least 30 minutes after re-vaccination. For example, a longer period of observation is warranted for individuals exhibiting any symptom suggestive of an evolving AEFI at the end of the 30-minute observation period.
Side Effects	***Injection site reactions*:** pain at injection site, tenderness and swelling of the lymph nodes (underarm) in the same arm of the injection, swelling (hardness), and redness. [1] ***Systemic side effects*:** fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, diarrhea, and fever.[1] Adverse reactions in adolescents 12 to 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%).[1] Adverse reactions in recipients aged 16 and older included pain at the injection site (84.3%), fatigue (64.7%), headache (57.1%), chills (34.7%), muscle pain (40.2%), fever (15.2%), joint pain (25.2%), injection site swelling (11.1%), injection site redness (9.9%), lymphadenopathy (0.4%), and nausea (1.2%).[1] There is a remote chance that the Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine could cause a severe allergic reaction or hypersensitivity reaction (e.g., rash, pruritus, urticaria, angioedema). It is important to have each person wait for 15 minutes after receiving their immunization and know how to contact clinic staff if they feel unwell.[2] Please see precautions and additional notes section regarding individuals who require a longer post-immunization observation period.
Reportable Adverse Events/Side	Report all serious adverse events requiring medical attention, unusual/unexpected events, or medication errors to RCDC. Review section 3.5 Management and Reporting of Adverse Events in the Nunavut Immunization Manual. Appendix D

Effects/Administration Errors	Reporting an Adverse Event Following Immunization provides additional information. ***Rare reactions:*** rare reactions that have been reported and confirmed after taking an mRNA vaccine are: • Myocarditis and pericarditis • Bell's palsy (facial paralysis) • Guillain- Barré syndrome • Anaphylaxis The AEFI form is available here: Report of adverse events following immunization (AEFI) (canada.ca) Section 3.5 of the Immunization Manual is available here: https://www.gov.nu.ca/health/information/manuals-guidelines If an inadvertent vaccine error is found, health care providers in Nunavut should: 1. Inform the client of the vaccine administration error as soon as possible. • Explain the possibility for local or systemic reactions. 2. Complete an incident report on Meditech and notify the RCDC. Some examples of inadvertent administration errors include incorrect route, higher-than-authorized dose volume administered, lower-than-authorized dose volume administered, dose administered past the expiration date, etc. 3. Complete an AEFI form and submit it to the RCDC only if the inadvertent vaccine administration error results in an AEFI.
Vaccine Coverage and Reporting	Vial tracking forms must be filled out for each vial of Pfizer-BioNTech COMIRNATY® and submitted by e-mail to the Regional Communicable Disease Coordinator and CDCLabs@gov.nu.ca. Please see Appendix E.
Documentation	Health care providers are required to document vaccine administration in Meditech and ensure the consent form is completed and stored as per health centre processes. Update recipient's Personal Immunization Record and provide date of next dose of vaccine. Follow operational team guidance on processes to track and call back clients for second dose. To help ensure the traceability of vaccines for patient immunization record-keeping as well as safety monitoring, health professionals should record the time and date of administration, quantity of administered dose (if applicable), anatomical site and route of administration, brand name and generic name of the vaccine, the product lot number and expiry date.[1]

Vaccinations in the context of COVID-19	In the context of a pandemic, staff must abide by the infection prevention and control requirements for the immunization clinics, including wearing the appropriate personal protective equipment as currently recommended in health centres, performing hand hygiene, and remaining 2 metres apart from others where feasible and except as required to offer immunizations. For additional information on infection prevention and control please consult: https://www.gov.nu.ca/sites/default/files/infection_prevention_and_control_resources.pdf. A point of care risk assessment is the usual practice for decisions about personal protective equipment. Immunizers should wear mask and eye shield. In communities with an ongoing outbreak of COVID-19, additional precautions may be considered in line with current guidance and approach of health centre.
Materials and resources	Nunavut Immunization Manual https://gov.nu.ca/health/information/manuals-guidelines COVID-19 Vaccine Information Sheet, Consent Form, After Care Sheet Nunavut Communicable Disease Manual: COVID-19 Public Health Protocol https://gov.nu.ca/health/information/manuals-guidelines Protocols and materials are available on the Department of Health website (www.gov.nu.ca/health)
Appendices	Appendix 1 Condition specific criteria and prescribed actions Appendix 2 Thawing, Dilution and Preparation of Dose Vaccine Consent Form Vaccine Information Sheet Vaccine Aftercare Sheet (with translations) Appendix B Guidance for Vaccination with COVID-19 Vaccines - Home Visit Appendix C Orientation to Obtaining Consent for Administration of COVID-19 vaccines Appendix D Reporting an Adverse Event Following Immunization Appendix E COVID-19 Vaccine Transport Protocol Appendix F Vaccine Clinic Screening Questions Appendix G Vaccine Clinic Booking Script Appendix H COVID-19 Booster Vaccine Doses Fact Sheet
References	1. Pfizer-BioNTech COMIRNATY® (2021). Pfizer-BioNTech COMIRNATY® COVID-19 vaccine product monograph.

https://www.pfizer.ca/sites/default/files/202109/COMIRNATY_PM_EN_252736_16-Sep-2021.pdf (accessed October 30th, 2021).

2. National Advisory Committee on Immunization (2021). *An advisory Committee Statement: Recommendations on the use of COVID-19 Vaccines.* https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf (accessed May 28th, 2021)

3. Society of Obstetricians and Gynecologists of Canada (2021). *SOGC Statement on COVID-19 Vaccination in Pregnancy. Reaffirmed May 25, 2021.*https://www.sogc.org/common/Uploaded%20files/Latest%20News/SOGC_Statement_COVID-19_Vaccination_in_Pregnancy.pdf (accessed June 6th, 2021).

Approved by Dr. Michael Patterson, Chief Public Health Officer, on November 1, 2021. Department of Health, Government of Nunavut

Appendix 1. Condition-specific criteria and prescribed actions.

The criteria listed below include indications, contraindications, and considerations around special populations for implementing the vaccine protocol. However, the criteria must be reviewed and further delineated according to the licensed prescriber's parameters. Additional criteria and prescribed actions may be necessary. A licensed prescriber must review the criteria and actions and determine the appropriate action to be prescribed.

	Criteria	**Prescribed Action**
Indications	Client is aged 12-17 years of age	Proceed to vaccinate if meets remaining criteria and consent obtained from individual as mature minor or from parent/guardian as required.
	Client is less than 12 years of age.	Do not vaccinate
Contraindications	Client had a systemic allergic reaction, anaphylaxis, to first dose of COVID-19 vaccine.	Do not vaccinate today and consult the Office of the CPHO/RCDC for further guidance.
	Client has an allergy to polyethylene glycol (PEG) or has had a severe allergic reaction to another component of the vaccine.	Do not vaccinate today and consult the Office of the CPHO/RCDC for further guidance.
	Client has received another vaccine in the past 14 days (not COVID-19).	Proceed to vaccinate if meets remaining criteria.
Special Populations	Client is currently or may be pregnant.	Proceed to vaccinate if meets remaining criteria.
	Client is breastfeeding.	Proceed to vaccinate if meets remaining criteria.
	Patient has problems with immune system from disease such as cancer or treatment/medications such as chemotherapy or corticosteroids	Proceed to vaccinate if meets remaining criteria. Advise client of potential for 3rd dose and submit referral to community MD.
	Patient has an auto-immune disorder.	Proceed to vaccinate if meets remaining criteria. Advise client of potential for 3rd dose and submit referral to community MD.

Appendix 2. Thawing, dilution and preparation of dose

<table>
<tr><th colspan="2">THAWING PRIOR TO DILUTION</th></tr>
<tr><td> 
</td><td>

Thaw vial(s) of Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine before use either by:

Allowing vial(s) to thaw in the refrigerator (2°C to 8°C [35°F to 46°F]). A carton of vials may take up to 3 hours to thaw, and thawed vials can be stored in the refrigerator for up to 1 month.
Allowing vial(s) to sit at room temperature (up to 25°C [77°F]) for 30 minutes.

Using either thawing method, vials must reach room temperature before dilution and must be diluted within 2 hours of exposure to room temperature.

</td></tr>
<tr><td> 
</td><td>

Before dilution, invert vaccine vial gently 10 times.
<u>Do not shake.</u>
Inspect the liquid in the vial prior to dilution. The liquid is a white to off-white suspension and may contain <u>white to off-white opaque amorphous particles</u>.
Do not use if liquid is discoloured or if other particles are observed.

</td></tr>
</table>

DILUTION	
	• Obtain sterile 0.9% Sodium Chloride Injection, USP. Use only this as the diluent. • Using aseptic technique, withdraw 1.8 mL of 0.9% Sodium Chloride Injection, USP into a transfer syringe (21-gauge or narrower needle). • Cleanse the vaccine vial stopper with a single-use antiseptic swab. • Add 1.8 mL of 0.9% Sodium Chloride Injection, USP into the vaccine vial.
	• Equalize vial pressure before removing the needle from the vial by withdrawing 1.8 mL air into the empty diluent syringe.
	• **Gently** invert the vial containing the Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine 10 times to mix. • <u>Do not shake</u>. • Inspect the vaccine in the vial. • The vaccine will be an off-white suspension. Do not use if vaccine is discoloured or contains particulate matter.



- Record the date and time of dilution on the Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine vial label.
- Store between 2°C to 25°C (35°F to 77°F).
- Discard any unused vaccine 6 hours after dilution.

PREPARATION OF INDIVIDUAL 0.3 mL DOSES OF PFIZER-BIONTECH COMIRNATY® COVID-19 VACCINE



- Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab, and withdraw 0.3 mL of the Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine, preferentially using low dead-volume syringes and/or needles.
- Each dose must contain 0.3 mL of vaccine.
- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
- Administer immediately, and no later than 6 hours after dilution.
- Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. In order to ensure consistent withdrawal of 6 doses of 0.3 mL, it is important to adhere to minimizing volume loss during dose extraction.

ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine Consent Form

Please fill in or put label:

Last Name____________________________

First Name____________________________

Community____________________________

DOB (dd/mm/yyyy)______________________

Please ensure name, community, and date of birth are completed above.

Health card number (if known): ___________ **House number (optional):** _________________

Phone number: ________________________ **Email address (optional)**: __________________

Gender: Man ☐ Woman ☐ Prefer to self-describe ☐ _________ **Age:** _____________

Parent/guardian information

Name:______________________________ **Phone:**_______________________________________

For the person receiving the vaccine, please answer:

Is this your first, second or third dose of the Pfizer vaccine? ☐1st ☐2nd ☐3rd ☐ Booster
***3rd dose only available for individuals with moderate - severe immunocompromise. For eligibility criteria, please see Nunavut Pfizer BioNTech Comirnaty® protocol.
If second, third or booster dose, what date was your previous? ______ dd / Month / yyyy ________

		Yes	No
1.	**Do you feel sick with a fever today?** (If yes, please provide details below)	☐	☐
2.	**Have you or your child had COVID-19?** (If yes, please indicate when symptoms started below) *You can still receive the vaccine if you've had or think you've had COVID-19 before.*	☐	☐
3.	**Are you, or could you be pregnant?** (You will still be offered the vaccine.)	☐	☐
4.	**If this is your second, third or booster dose, did you have any side effects after any previous doses?** (If yes, please provide details below.)	☐	☐
5.	**Do you have any problems with your immune system or are you taking any medications that can affect your immune system (e.g., high dose steroids, chemotherapy)?** (If yes, please provide details below.)	☐	☐
6.	**Do you have a bleeding disorder or are you taking any medications that could affect blood clotting?** (If yes, please provide details below.)	☐	☐
7.	**Have you have had a serious reaction to a vaccine in the past?** (If yes, please provide details below.)	☐	☐
8.	**Are you allergic to polyethylene glycol (PEG)** which is an ingredient in the vaccine?**	☐	☐
9.	**Have you ever had a severe allergic reaction for which you were prescribed an Epipen?** (If yes, please provide details below.)	☐	☐
10.	**Have you ever been diagnosed with myocarditis or pericarditis**** following administration of a COVID-19 vaccine?** (If yes, please do not proceed with vaccination today).	☐	☐

** Polyethylene glycol (PEG) can rarely cause allergic reactions and is found in products such as medications, bowel preparation products for colonoscopy, laxatives, cough syrups, cosmetics, skin creams, medical products used on the skin and during operations, toothpaste, contact lenses and contact lens solution.

**** Very rare cases of myocarditis and pericarditis following vaccination with mRNA vaccines have been reported. Short-term data suggest that it is self-resolving in patients and the decision to continue a COVID-19 vaccine with history of myocarditis or pericarditis should be made by the office of the Chief Public Health Officer.

Department of Health
Munaqhiliqiyitkut
Ministère de la Santé
Nunavut

Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine Consent Form

Please fill in or put label:

Last Name________________________________

First Name________________________________

Community________________________________

DOB (dd/mm/yyyy)__________________________

Comments from questions above:

CONSENT FOR Pfizer COVID-19 Vaccine:

For additional information about mature minors please refer to Appendix C and Section 3.2.3 of the Nunavut Immunization Manual.

- I understand the information in the Information Sheet on the Pfizer BioNTech COVID-19 Vaccine.
- I understand the benefits and possible reactions for the Pfizer-BioNTech COVID-19 Vaccine and the risk of not getting immunized.
- I have had the opportunity to ask questions and to have them answered to my satisfaction.
- I consent to Pfizer-BioNTech being given to: My Child, ☐ My Ward ☐ or Myself ☐

____**Print Name**

Signature of Client or Parent/Legal Guardian **Date (dd/mm/yyyy)**

Additional questions to help understand the populations receiving the vaccine

Risk Group *Tick all that apply*	**Yes**	**No**
Living in an Elders' facility	☐	☐
Working in an Elders' facility	☐	☐
Healthcare worker	☐	☐
Living in a shelter	☐	☐
Living in a correctional facility	☐	☐
Working in a shelter or correctional facility	☐	☐
55 years of age or older	☐	☐
Resident of Nunavut who is a rotational worker (e.g. in mines)	☐	☐
Underlying medical condition *If yes, circle all those that apply in the list the below* heart disease lung disease cancer high blood pressure diabetes problems with your immune system kidney disease liver disease taking medication that affects immune system	☐	☐

Nunavut
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine Consent Form

Please fill in or put label:

Last Name_______________________________

First Name______________________________

Community______________________________

DOB (dd/mm/yyyy)_________________________

For Administrative Use Only:

	DOSE	LOT#	SITE & ROUTE	GIVEN BY & WHEN Name and designation/Date and time
1st Dose	0.3 ml			Name:
				Date: *dd /Month / yyyy* Time:
2nd Dose	0.3 ml			Name
				Date: *dd /Month / yyyy* Time:
3rd Dose	0.3 ml			Name:
				Date: *dd/Month/yyyy* Time:
Booster	0.3 ml			Name:
				Date: *dd/Month/yyyy* Time:

Comments:

ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY®
ᓄᕙᒡᔪᐊᕐᓇᖅ–19–ᒧᑦ ᑳᐳᑎ ᑲᐱᔭᐅᔪᓐᓇᕐᓂᕐᒧᑦ ᐊᖏᕈᑎ

ᑎᑎᕋᕐᓗᒍ ᓂᐱᑎᒐᕐᓘᓐᓃᑦ ᑕᒪᐅᙱᒐᕐᓗᒍ:

ᐊᑎᕈᓯᖓ________________________

ᐊᑎᖓ________________________

ᓄᓇᖓ:

ᐃᓅᕕᖓᑕ ᐅᓪᓗᖓ ________________

ᓇᓗᓇᐃᑦᑎᐊᕐᓗᒋᑦ ᐊᑎᖓ, ᓄᓇᖓ ᐊᒻᒪ ᐃᓅᓕᕐᕕᖓᑕ ᐅᓪᓗᐊ ᑕᒫᕐᒥᒃ ᑎᑎᕋᖅᓯᒪᓗᑎᒃ.

ᐋᓐᓂᐊᕕᓕᐊᕈᓐᓇᐅᑖ (ᖃᐅᔨᒪᔭᐅᒃᐸᑦ): __________

ᐃᓪᓗᕕᑦ ᓇᐃᓴᐅᑎᖓ (ᑎᑎᙵᑦᑐᓐᓇᖅᑕᐃᑦ):

ᐅᖃᓚᐅᑎᐅᑉ ᓈᓴᐅᑎᖓ:

ᐃᕐᖠᓈᖅᑕᐅᒃᑯᑦ ᑐᕋᕈᑖ (ᑎᑎᖅᑕᐅᙱᑦᑐᓐᓇᖅᑐᖅ):

ᐊᕐᓇᐅᖓᖖᑦ ᐊᖑᑕᐅᖓᖖᓪᓘᓐᓃᑦ: ᐊᖑᑎ☐ ᐊᕐᓇᖅ☐ ᖃᓄᖅ ᐃᒻᒥᓂᒃ ᑕᐃᓰᖑᕚ☐ ________ ᐅᑭᐅᖓ: ___________

ᐊᖓᔪᖅᑳᖅ/ᑲᒪᔩᐅᔫᑉ ᒥᒃᓵᓄᑦ ᑎᑎᕋᕐᓗᒋᑦ:

ᐊᑎᖅ:____________________________ ᐅᖃᓚᐅᑖ:__________________________________

ᑲᐱᔭᐅᓕᖠᔪᖅ, ᑭᐅᔭᕆᐊᓕᒃ ᑖᓯᒥᖓ:

***ᑲᐱᔭᐅᕖᑦ ᓯᕗᓪᓕᖅᐹᒥ ᐅᕝᕙᓘᓐᓃᑦ ᑐᒡᓕᐊᓂ ᑖᓯᒥᖓ Pfizer ᓄᕙᒡᔪᐊᕐᓇᖅᑖᖅᑕᐃᓕᒪᒃᓯᑎᒥᒃ?* ☐ᓯᕗᓪᓕᖅᐹᒥ ☐ᑐᒡᓕᐊᓂ ☐ ᐱᖓᔪᖓᓐᓂᒃ ☐ ᓵᙵᓂᖅᓴᒧᑦ
***ᐱᖓᔪᖓᓂ ᑲᐱᔭᐅᔪᓐᓇᖅᑐᑦ ᑭᓯᐊᓂ ᐱᓗᐊᙱᑦᑐᒥᒃ - ᐱᕐᔪᐊᒥᒃ ᑎᒥᒥᒍᑦ ᐋᓐᓇᐅᒪᒃᓯᑎᖃᑦᑎᐊᕈᓐᓃᖅᑐᓄᑦ. ᐊᔪᙱᑎᑕᐅᔪᓄᑦ ᒪᓕᒋᐊᓖᑦ, ᑕᑯᓗᒍ ᓄᓇᕗᒻᒥ Pfizer BioNTech Comirnaty® ᒪᓕᒃᑕᐅᔭᕆᐊᓕᑦ.
*ᑐᒡᓕᐊᓂ, ᐱᖓᔪᖓᓂᓪᓗᓐᓃᑦ ᐅᕝᕙᓘᓐᓃᑦ ᓵᙵᓂᖅᓴᒧᑦ ᑲᐱᔭᐅᔪᑦ, ᑭᓯᑎᓪᓗᒍ ᐅᓪᓗᖅ ᑭᖑᓪᓕᕐᒥ ᑲᐱᔭᐅᓂᖅᐱᑦ?*_____ ~~ᐅᓪᓗᖅ / ᑕᖅᑭᖅ / ᐅᑭᐅᖅ~~ ______

#		ᐄ	ᐋᒃᑲ
1.	**ᐋᓐᓂᐊᙳᖅᑲᖅᐲᑦ ᓇᐅᒃᑯᑐᐃᓐᓇᖅ ᐊᒻᒪ ᐆᑎᕐᓇᑲᑖᒃᐱᑦ?** (ᐊᖏᕈᕕᑦ, ᐊᑖᓂᑦᑐᑦ ᓇᓗᓇᐃᖅᓯᒪᔪᑦ ᑎᑎᕋᕕᒋᓗᒋᑦ)	☐	☐
2.	**ᓄᕙᒡᔪᐊᕐᓇᖅᑐᖃᓚᐅᖅᐲᑦ ᐅᕝᕙᓘᓐᓃᑦ ᕿᑐᕐᖓᕕᑦ ᓄᕙᒡᔪᐊᕐᓇᖅᑐᖃᓚᐅᖅᐸ?** (ᐊᖏᕈᕕᑦ, ᓇᓗᓇᐃᕐᓗᒍ ᖃᖓ ᖃᓄᐃᑦᔪᑎᒋᓯᑎᑦ ᐱᒋᐊᓚᐅᕐᒪᖔᑕ) *ᑲᐱᔭᐅᙱᓐᓇᕈᓐᓇᖅᑐᑎᑦ ᓄᕙᒡᔪᐊᕐᓇᖅᑖᖅᑕᐃᓕᒪᒃᓯᑎᒥᒃ ᑐᖏᕋᖕᒪᒡᒍᑦ ᓄᕙᒡᔪᐊᕐᓇ ᖃᓚᐅᕋᓗᐊᕈᕕᑦ.*	☐	☐
3.	**ᓄᑕᕋᒃᓴᖅᐸᑦ, ᓯᖓᐃᖅᑰᖅᐸᑦ?** (ᑲᐱᔭᐅᙱᓐᓇᕈᓐᓇᖅᑐᑎᑦ ᐱᔪᒪᒍᕕᑦ.)	☐	☐
4.	**ᑐᒡᓕᐊᓂ ᐱᖓᔪᖓᓂᓪᓗᓐᓃᑦ ᐅᕝᕙᓘᓐᓃᑦ ᓵᙵᓂᖅᓴᒧᑦ ᑲᐱᔭᐅᒍᕕᑦ, ᖃᓄᐃᔾᔪᑎᖃᓚᐅᖅᐱᑦ ᓯᕗᓪᓕᕐᒥ ᑲᐱᔭᐅᓚᕕᑦ?** (ᐊᖏᕈᕕᑦ, ᐊᑖᓂᑦᑐᑦ ᓇᓗᓇᐃᖅᓯᒪᔪᑦ ᑎᑎᕋᕕᒋᓗᒋᑦ.)	☐	☐
5.	**ᐋᓐᓇᐅᒪᔾᔪᑎᖏᑦ ᑎᒥᕕᑦ ᐱᐅᙱᑦᑑᕙᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐃᓅᓕᓴᐅᑎᓂᒃ ᐄᓯᔭᕆᐊᖃᖃᑦᑕᖅᐲᑦ ᐋᓐᓇᐅᒪᔾᔪᑎᖑᓄᑦ ᐊᒃᑐᐃᓂᖃᕈᓐᓇᖅᑐᓂᒃ (ᓲᕐᓗ, ᐋᓈᒃᑑᑎᓄᑦ ᓴᙱᒃᑎᒋᐊᕈᑎᑦ, ᓄᖑᓴᖅᑕᐅᓂᕐᓘᓐᓃᑦ)?** (ᐊᖏᕈᕕᑦ, ᐊᑖᓂᑦᑐᑦ ᓇᓗᓇᐃᖅᓯᒪᔪᑦ ᑎᑎᕋᕕᒋᓗᒋᑦ.)	☐	☐
6.	**ᐊᐅᒋᔭᐃᑦ ᐃᓕᖅᑯᓯᖅᓱᙱᕐᔪᑎᖅᖢ ᐅᕝᕙᓘᓐᓃᑦ ᐋᔭᒐᖃᑦᑕᕆᐊᖃᖅᐲᑦ ᐊᐅᒃᐱᑦ ᒪᒥᑦᑎᔾᔪᑎᖏᓐᓄᑦ ᐊᒃᑐᐃᓂᖃᕈᑐᐃᓐᓇᕆᐊᖃᖅᑐᒥᒃ?** (ᐊᖏᕈᕕᑦ, ᐊᑖᓂᑦᑐᑦ ᓇᓗᓇᐃᖅᓯᒪᔪᑦ ᑎᑎᕋᕕᒋᓗᒋᑦ.)	☐	☐
7.	**ᑲᐱᔭᐅᓚᐅᖅᑎᓪᓗᑎᑦ ᑎᒥᑦ ᐱᐅᒃᓴᙱᓐᓂᕐᒧᑦ ᖃᓄᐃᔾᔪᑎᖃᓚᐅᖅᓯᒪᕕᑦ?** (ᐊᖏᕈᕕᑦ, ᐊᑖᓂᑦᑐᑦ ᓇᓗᓇᐃᖅᓯᒪᔪᑦ ᑎᑎᕋᕕᒋᓗᒋᑦ.)	☐	☐
8.	**ᑎᒦᑦ ᐱᐅᒃᓴᙱᓖᖅ polyethylene glycol (PEG)**-ᒥᒃ ᑖᓐᓇ ᑳᐳᑎᐅᑉ ᐃᓗᐊᓃᖅᑕᐅᔪᖅ?**	☐	☐
9.	**ᑎᒦᑦ ᐱᐅᒃᓴᙱᓐᓂᕐᒧᑦ ᖃᓄᐃᔾᔪᑎᖃᕐᓂᖓᓄᑦ ᑐᓂᔭᐅᓚᐅᖅᓯᒪᕖᑦ EpiPen ᑳᐳᑎᒥᒃ?** (ᐊᖏᕈᕕᑦ, ᐊᑖᓂᑦᑐᑦ ᓇᓗᓇᐃᖅᓯᒪᔪᑦ ᑎᑎᕋᕕᒋᓗᒋᑦ.)	☐	☐
10.	**myocarditis-ᑖᓚᐅᖅᓯᒪᕖᑦ ᐅᕝᕙᓘᓐᓃᑦ pericarditis**** ᓄᕙᒡᔪᐊᕐᓇᖅ–19-ᒧᑦ ᑲᐱᔭᐅᓚᐅᖅᖢᑎᑦ?** (ᐊᖏᕈᕕᑦ, ᐅᓪᓗᒥ ᑲᐱᔭᐅᑦᑕᐃᓕᑲᓚᐅᕆᑦ).	☐	☐

**Polyethylene glycol (PEG) ᑎᒥᐅᑉ ᐱᐅᒥᙱᓪᓗᓂᐅᒃ ᖃᓄᐃᔾᔪᑎᐅᓕᔪᐊᙱᑦᑑᔪᖅ ᐃᓚᒋᔭᐅᕙᒃᓱᓂᓗ ᓲᕐᓗ ᐃᓅᓕᓴᐅᑎᓂᒃ, ᐃᖅᑰᒃᑯᑦ ᑕᕿᖅᑐᖅᑕᐅᓂᐊᕐᓗᓂ ᐅᐸᓗᙱᐃᔭᕈᑎᒧᑦ, ᐊᓇᕈᓇᐃᓪᓕᐅᖅᑲᔪᓄᑦ ᐊᓇᕈᓇᖅᓯᔾᔪᑎᓂᒃ, ᓄᕙᒃᓯᐅᑎᓂᒃ, ᐱᐅᓴᐅᑎᓂᒃ, ᐅᕕᓂᒃᓯᐅᑎᓂᒃ, ᐅᕕᓂᓪᓗᒃᑐᓄᑦ ᐊᓪᓚᕈᓰᔭᒐᕐᓂᒃ ᐊᒻᒪ ᐱᓚᒃᑕᐅᔪᖃᓖᑎᓪᓗᒍ ᐅᕕᓂᖑᒧᑦ ᐅᐸᓗᙱᐃᔭᕈᑕᐅᕙᒃᑭᓪᓗᓂ, ᑭᒍᑎᓯᐅᑎᓂᒃ, ᐃᔨᒧᑦ ᐃᓪᒐᑯᓗᙵᓂᕙᒃᑭᓪᓗᓂ.

****ᑕᐃᒪᐃᑦᑐᖃᕋᔪᙱᑦᑐᖅ myocarditis-ᒥᑦ ᐊᒻᒪ pericarditis-ᒥᑦ ᑲᐱᔭᐅᔪᖃᓚᐅᖅᑎᓪᓗᒍ mRNA–ᒧᑦ ᐅᖃᐅᓯᐅᔪᖃᕋᔪᙱᑦᑐᖅ. ᕿᓚᒻᒥᐅᔪᖅ ᑎᑎᕋᖅᓯᒪᔪᑦ ᐃᒪᐃᕐᑯᔨᕗᑦ ᐃᒻᒥᓂᒃ ᐊᐅᓚᑦᑎᓗᓂ ᖃᓂᒪᔪᖅ ᐊᒻᒪᓗ ᑲᔪᓯᑦᑎᔪᒪᓗᓂ ᓄᕙᒡᔪᐊᕐᓇᖅ-19–ᒧᑦ ᑳᐳᑎᒥᒃ myocarditis–ᖃᓚᐅᖅᓯᒪᔪᖅ ᐊᒻᒪ pericarditis-ᖃᓚᐅᖅᓯᒪᔪᖅ ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ ᐊᖓᔪᖅᑳᖓᓄᑦ ᐋᖅᑭᒃᑕᐅᔭᕆᐊᖅᐸᖅ.

ᐋᓐᓂᐊᖃᕐᓇᖏᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech
COMIRNATY®
ᓄᕙᒡᔪᐊᕐᓇᖅ–19–ᒧᑦ ᑳᐳᑎ
ᑲᐱᔭᐅᔪᓐᓇᕐᓂᕐᒧᑦ ᐊᖏᕈᑎ

ᑎᑎᕋᕐᓗᒍ ᓂᐱᑎᒐᕐᓗᓐᓂᑦ ᑕᒪᐅᙱᕐᓗᒍ:

ᐊᑎᕈᓯᖓ______________________

ᐊᑎᖓ______________________

ᓄᓇᖓ:

ᐃᓅᕕᖓᑕ ᐅᓪᓗᖓ ________________

ᐅᖃᐅᓯᕆᔪᒪᔭᑎᑦ ᖁᕐᓂ ᑐᓴᖅᑕᕕᑦ ᒥᒃᓵᓄᑦ:

ᐊᖏᕐᓂᖅ Pfizer ᓄᕙᒡᔪᐊᕐᓇᖅᑖᖅᑕᐃᓕᒪᔾᔪᑎᒧᑦ ᑲᐱᔭᐅᓂᕐᒥᒃ:

ᑐᓴᒃᑲᓂᕈᒪᒍᕕᑦ ᓯᓚᑐᔪᓄᑦ ᐅᕿᐅᕿᓗᐊᕋᓗᐊᖅᓱᑎᒃ ᖃᓅᔭᕆᐊᖃᕐᒪᙶᑕ ᑕᑯᓗᒍ ᐃᓚᒍᑖᑕ ᐊᒻᒪᓗ ᐃᓛᒃᑯᖓᔪᖅ 3.2.3 ᓄᓇᕗᒻᒥ ᑲᐱᔭᐅᓂᕐᒧᑦ ᖃᐅᔨᒪᔾᔪᑎ.

- ᑐᑭᓯᔭᒃᑲ ᑐᓴᐅᒪᔭᕆᐊᖓᓪᓚᑦ ᐃᓗᐊᓃᑦᑐᑦ Pfizer BioNTech ᒥᒃᓵᓄᑦ ᓄᕙᕐᔪᐊᕐᓇᖅᑖᖅᑕᐃᓕᒪᔾᔪᑎᒧᑦ ᓇᓗᓇᐃᔭᖅᑕᐅᔪᑦ.
- ᑐᑭᓯᔭᒃᑲ ᖃᓄᖅ ᐱᕚᓪᓕᕈᑎᖃᕈᓐᓇᕐᒪᖔᕐᒪ ᐊᒻᒪᓗ ᑎᒥᒪ ᖃᓄᐃᔾᔪᑎᒋᔪᓐᓇᖅᑕᖏᓐᓂᒃ ᑲᐱᔭᐅᕆᒃᑯᒪᓗ ᐊᑦᑕᕐᓇᖅᓯᔪᓐᓇᖅᑐᓂᒃ ᑕᕝᕙᖓᑦ Pfizer-BioNTech ᑳᐳᑎᖓᓂᒃ ᑐᑭᓯᐅᒪᓪᓗᖓ ᑲᐱᔭᐅᕆᒃᑯᒪ ᐊᑦᑕᕐᓇᖅᑐᒧᐊᕈᓐᓇᕐᓂᓐᓂᒃ.
- ᐱᕕᖃᑦᑎᐊᕚᖑᒪ ᐊᐱᖅᓱᕈᓐᓇᖅᓯᓐᖓ ᐊᐱᖅᑯᑎᒋᔭᒃᑲᓗ ᑭᐅᔭᐅᑦᑎᐊᖅᓯᑎᒃ ᑐᓴᕈᒪᔭᒃᑲ ᑐᓴᖅᓯᒋᑦ.
- ᐊᖏᖅᐳᖓ Pfizer-BioNTech ᑲᐱᔭᐅᔾᔪᑎᖓᓂᒃ ᑲᐱᔭᐅᔪᓐᓇᖅᓯᓂ ᐅᓇ: ᖀᑐᕐᖓᕋ, ☐ ᑲᒪᒋᔭᕋ ☐ ᐅᕙᖓ ☐

_______________________________________ **ᐊᑮᑦ ᑎᑎᕋᕐᓗᒍ** **ᐊᑎᓕᐅᕈᓯᐊ**

ᐃᓅᑉ ᐅᕝᕙᓘᓐᓃᑦ ᐊᖓᔪᖅᑳᕆᔭᐅᔪᓘᓐᓃᑦ/ᒪᓕᒐᑎᒎᑦ ᐸᖅᑭᔾᔨᐅᔪᖅ **ᐅᓪᓗᖅ (ᐅᓪᓗᖅ/ᑕᖅᑭᖅ/ᐊᕐᕌᒍ)**

ᐊᐱᖅᑯᑎᒃᓴᒃᑲᓐᓂᑦ ᑐᑭᓯᕚᓪᓕᕋᓯᐊᕐᓂᕐᒧᑦ ᐃᓄᐃᑦ ᑲᐱᔭᐅᔾᔪᑎᖏᑕ ᒥᒃᓵᓄᑦ

ᓇᓕᐊᖕᓂᖔᖅᐸ ᐊᑦᑕᕐᓇᖅᑐᑦᑐᓐᓇᕐᓂᖓ *ᑎᑎᕐᓗᒋᑦ ᐊᒃᑑᑎᔪᑦ*	**ᐄ**	**ᐋᒃ**
ᐃᓄᑐᖃᒃᑯᕕᖕᒥᐅᑕᖅ	☐	☐
ᐃᓄᑐᖃᒃᑯᕕᖕᒥ ᐃᖅᑲᓇᐃᔭᖅᑎ	☐	☐
ᐋᓐᓂᐊᖃᕐᓇᖏᑦᑐᓕᕆᔨᒃᑯᓐᓂ ᐃᖅᑲᓇᐃᔮᓪᓕ	☐	☐
ᖃᒫᕕᖕᒥᐅᑕᐅᔪᖅ	☐	☐
ᑎᒍᔭᐅᕕᖕᒦᑦᑐᖅ	☐	☐
ᖃᒫᕕᖕᒥᒃ ᑎᒍᔭᐅᓯᒪᕕᖕᒥᖖᓂᑦ ᐃᖅᑲᓇᐃᔮᓪᓕ	☐	☐
ᐅᑭᐅᓪᓕ 55–ᓂᒃ ᐅᖓᑖᓂᓪᓗᓐᓂᑦ	☐	☐
ᓄᓇᕗᒻᒥᐅᑕᖅ ᐊᐅᓪᓚᖃᑦᑕᖅᑐᖅ ᐅᑎᖅᐸᒃᑐᓂ (ᓲᕐᓗ, ᐅᔭᕋᖕᓂᐊᕐᕕᖕᒥ)	☐	☐
ᖃᓂᒪᔾᔪᑎᖃᑦᑕᖅᑐᑦ *ᐊᖏᕈᕕᕋ, ᐊᖕᒪᓗᖅᓯᓗᒋᑦ ᑕᒪᕕᒃ ᐋᒃᑑᑎᔪᐃᑦ ᓇᓗᓇᐃᕐᓗᒋᑦ* ᐆᒪᑎᕐᓗᓐᓂᖅ ᐳᕙᓪᓗᓐᓂᖅ ᐋᓐᓂᐊᖃᕐᓂᖅ ᑎᒥᒃᑯᑦ ᓂᕆᕙᓪᓕᐊᔾᔨᒃ	☐	☐

ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY®
ᓄᕙᒡᔪᐊᕐᓇᖅ–19–ᒧᑦ ᑲᐴᑎ
ᑲᐱᔭᐅᔪᓐᓇᕐᓂᕐᒧᑦ ᐊᖏᕈᑎ

ᑎᑎᕋᕐᓗᒍ ᓂᐱᑎᒐᕐᔫᓃᑦ ᑕᒪᐅᙵᕐᓗᒍ:

ᐊᑎᕈᓯᖓ______________________

ᐊᑎᖓ______________________

ᓄᓇᖓ:

ᐃᓅᓯᖓᑕ ᐅᓪᓗᖓ ________________

ᐊᐅᓚᑕ ᑎᓪᓕᕐᓂᖓ ᖁᕝᕙᓯᒍᐊᖅᑐᖅ	ᑎᒥᒃᑯᑦ ᓱᑲᖕᒐᐊᖅᑐᑦ	ᑎᒥᐅᑉ ᐊᓐᓇᐅᒪᔾᔪᑎᖏᓐᓂᒃ
ᐋᓐᓂᐊᖅᑲᖅᑕᕐᓂᖅ		
ᑕᖅᑐᕐᓗᓐᓂᖅ	ᑎᖑᓪᓗᓐᓂᖅ	ᐊᓐᓇᐅᒪᔾᔪᑎᓄᑦ ᐃᑲᔫᑎᒥᒃ ᐆᔭᒐᖅᑕᖅᑐᖅ

ᐊᓪᓚᕝᕕᖕᒥ ᑭᓯᐊᓂ ᑎᑎᕋᕝᕕᐅᕆᐊᓪᓚᒃ:

	ᐃᓗᐊᖅ ᓴᐅᑎᑐ ᖅᑕᐅᔪ ᑦ	LOT#	ᓇᐅᒃᑯᑦ ᐊᒻᒪᓗ ᐊᖅᑯᑖ	ᑲᐱᓯᔫᑉ ᐊᑎᖓ ᐊᒻᒪ ᖃᖓᐅᑎᓪᓗᒍ ᐊᑎᖓ ᓇᓕᐊᖕᓂᖓᕐᓂᖓᓗ/ᐅᓪᓗᖅ ᖄᓯᒧᐊᖅᑎᓪᓗᒍᓗ
ᓯᕗᓪᓕᖅ ᑲᐴᑎ	0.3 ᐃᒪᖅᑯ ᖅᑐᓂ ᖓ			ᐊᑎᖅ: ᐅᓪᓗᖅ: (ᐅᓗᖅ/ᑕᖅᑭᖅ/ᐊᕐᕌᒍ) ᖄᓯᒧᐊᖅᑎᓪᓗᒍ:
ᑐᓪᓕᐊᓂ ᑲᐴᑎ	0.3 ᐃᒪᖅᑯ ᖅᑐᓂ ᖓ			ᐊᑎᖓ ᐅᓪᓗᖅ: ᐅᓪᓗᖅ/ᑕᖅᑭᖅ/ᐊᕐᕌᒍ ᖄᓯᒧᐊᖅᑎᓪᓗᒍ:
ᐱᖓᓱᖓ ᑦ ᑲᐱᔭᐅᔾᔪ ᑎ	0.3 ᐃᒪᖅᑯ ᖅᑐᓂ ᖓ			ᐊᑏᑦ: ᐅᓪᓗᖅ: ᐅᓪᓗᖅ/ᑕᖅᑭᖅ/ᐊᕐᕌᒍ ᖄᓯᒧᐊᖅᑎᓪᓗᒍ:
ᓴᙲᓂᖅ ᓴᒧᑦ	0.3 ᐃᒪᖅᑯ ᖅᑐᓂ ᖓ			ᐊᑏᑦ: ᐅᓪᓗᖓ: ᐅᓪᓗᖅ/ᑕᖅᑭᖅ/ᐊᕐᕌᒍ ᖄᓯᒧᐊᖅᑎᓪᓗᒍ:

ᐅᖃᐅᓯᒃᓴᑦ:

Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY® COVID-19 Qalagjuarnikkut Kapurhirniq Angirutikhamut Titiraq

Titiradjavatit titiraqhimajumikluuniin ilirilugu:

Kinguliq Atia_____

Hivulliq Atia_____

Nunallaami_____

ANNIVIA (dd/mm/yyyy)_____

Pihimalugit atiit, nunangit, ubluillu anniviit iniqtiqhimayut qulaani.

Aanniaqtailinirmut Takujaunikkut Nampaa (ilihimaguviuk): _____ **Igluvit nampaa (ihumangnik):** _____

Hivajautivit Nampaa: _____ **Qaritaujakkut titirarvia (ihumangnik)**: _____

Arnaq/Angut: Angut ☐ Arnaq ☐ Uqarumagumiuk inminik-naunairlugu ☐ _____ **Ukiungit:** _____

An'ngayuqqaaq/Munaqtigiyauyup Kangiqhidjutait

Atiq:_____ Hivayaut**:**_____

Inuk kapuqhiqtughauyuq, kiulugit:

Una hivuliuva, tugliq pingahuuvaluuniin kapuqhiutit haffuminga Pfizer havautaanik? ☐Hivulliq ☐ Tuglia ☐ Pingahuat ☐ Ikajuutikhamun

***Pingahua tapkunungainaq atautinun - aghut ayuqhautiqaqtut aanniarutinun. Kapuqhiriangini qanuriniitigut, takulugu Nunavunmi Pfizer BioNTech Comirnaty® protocol.

Tugliukpat, pingahuat unaluuniin ikajuutikhamun kapuutikhaq, huna ublua kingullirmun kapuutigijat?

_____ *dd / Tatqighiutaa / yyyy* _____

		Hii	Imannaq
1.	**Aanniangadjitpit kidjakhimavit ublumi?** (Angiruvit, tunidjavatit naunaittiarutikhat ataani)	☐	☐
2.	**Ilvit nutaqqaluuniin aanniarutiqaraluaqqit qalagyuarnirmun COVID 19?** (Angiruvit, nauniadjavatit qanga mihingnautiqalikhimavit ataani) *Kaupuqhiinariaqaqtutit aanniarutiqanahugiguvin aanniarutiqaqhimaguvinluuniin qalagyuarnirmik COVID-19 hivuani.*	☐	☐
3.	**Hingaiyauvit, hingaiyarnahugivinluuniin?** (Kapuqhirumaguvin kauqhiinarialiuyutit.)	☐	☐
4.	**Una tugliuva kapuqhirutit,pingahuat unaluuniin ikajuutikhamun kapuutikhaq, timingnun ihuirutigihimaviuk kinguani hivuliup kapuutip?** (Angiruvit, tunidjavatit naunaittiarutikhanik ataani.)	☐	☐
5.	**Ayuqhautiqaqqit timivit auladjutainun havautituqqiluuniin quyaginaq havautinik tapkua hulaqutauniaqtut timivit auladjutaanun (imaa, steriodsnik, taqqaktigut havauhirhugit, qaumanikuluuniin aanniarutaanun turaaqhugit)?** (Angiruvit, tunidjavatit naunaittiarutikhanik ataani.)	☐	☐
6.	**Aungnirmun ayuqhautiqaqqit havautituqiluuniin tapkua hulaqutauniaqtunun aungmun augianginangunirmun?** (Angiruvit, tunidjavatit naunaittiarutikhanik ataani.)	☐	☐
7.	**Aghut ihuirutigihimaviuk timingnun kapuqhirnirmun kinguani?** (Angiruvit, tunidjavatit naunaittiarutikhanik ataani.)	☐	☐
8.	**Timingnun una nakuungiutivakhimava polyethylene glycol (PEG)** kitut iluaniitut kapuutip havautaani?**	☐	☐
9.	**Akhut ihuirutigihimavigu kitut tuniyauhimayut uuminga EpiPen?** (Angiruvit, tunidjavatit naunaittiarutikhanik ataani.)	☐	☐
10.	**Ilituriyauhimavit hapkuninga myocarditismik unaluuniin pericarditis**** kapuqhiravin qalagyuarnirmun COVID-19 kapuutaanik?** (angiruvin, kapuqhiruiqlutit ublumi).	☐	☐

ᐊᓐᓂᐊᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᐱᓕᕆᕝᕕᒃ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY®
COVID-19 Qalagjuarnikkut
Kapurhirniq
Angirutikhamut Titiraq

Titiradjavatit titiraqhimajumikluuniin ililugu:
Kinguliq Atia___________________________
Hivulliq Atia___________________________
Nunallaami___________________________
ANNIVIA (dd/mm/yyyy)______________________

** Polyethylene glycol (PEG) ihuinaarutiqangituq uvalu paqinaqtut havautini, aniayarnimunlu ihivriuqhiriangini ingaluanginik, aqiaruqhiutit, qalakhiutit, piniqhautit, uviningmun urhuqtitutit, mamihaidjutinilu atuqtauyut uviningmun pilakhiqtilugillu, kigutigighautini, iingnun iliurariaqaqtut takpighautit halumaqtirutaini.

**** Takunaqluayuitullu haffuminga myocarditismik unalu pericarditismik kapuqhiraangamik haffuminga mRNA kapuutaanik uniudjutigiyauyunik. Naitumik-kikliqaqtut naunaiyautit ihumagiyauyut inmi-ihuaqhiyuumiqtut aanniaqtut ukualu ihumaliurutit aulahimaaqtumik qalgyuarnirmun COVID-19 kapuqhiqtut kinguani aanniarutiqaqtut ukuninga myocarditis unaluuniin pericarditis havaktauyughat hapkunanga havagviinin Atanilluaq Inungnun Aanniaqtailinikkut Havaktimin.

Uqautigiyait apiqqutinut qulaani:

ANGIRUTIT HAFFUMUNGA Pfizermun Qalagjuarnirmun COVID-19 Kapuutit:

Ilailiutihimayunik kangiqhidjutinik mighaanun inulramirnun takulugit Naunaitkutaani Cmi unalu Titiraqhimayuq 3.2.3 haffumani Nunavut Kapuqhirutikkut Maligahat.

- Kangiqhiyatka kangiqhidjutit Langiqhidjutit Titiraqhimayut haffumuunga Pfizer BioNTech Qalagjuarnirmun COVID-19 Kapuutit.
- Kangiqhimayatka ikayuutait hulaqutailu haffuma Pfizer-BioNTech qalagyuarnirmun COVID-19 Kapuutit qayangnautaillu kapuqhingitpat.
- Apirhuutimniklu apiruqtitauyunga kiuyaublungalu nakuugiyamnik.
- angirutigiyara una Pfizer-BioNTech tuniyauyuq uvunga: Nutarara, ☐ Munaqhiviga ☐ Uvangaluuniin ☐

____Titiraqlugu

Atqit Sainiutaa Kapuqhiqtughap/Munaqtia Ublua (dd/mm/yyyy)

Aallanik apiqqutikhaqaruvit kangiqhittiarutikharnik inugiangingit kapurhiktukhanik taffuminga kapuutimik

Qajangnaqtunut *Titiraqlugit tamaita atuqtaulajut*	**Hii**	**Imannaq**
Najugaqaruvit Inirnikhat najugaani	☐	☐
Havakkuvit Inirnikhat najugaani	☐	☐
Munarhini havaktiuguvit	☐	☐
Najugaqaruvit qimaavingni	☐	☐

ᐊᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Pfizer-BioNTech COMIRNATY®
COVID-19 Qalagjuarnikkut Kapurhirniq
Angirutikhamut Titiraq

Titiradjavatit titiraqhimajumikluuniin ilirilugu:

Kinguliq Atia____________________________

Hivulliq Atia____________________________

Nunallaami____________________________

ANNIVIA (dd/mm/yyyy)________________________

Najugaqaruvit itiqtauvingmi	☐	☐
Havakkuvit qimavingmi itiqtauvingmiluuniit	☐	☐
55 ukiuqaqtunut angajukhiujunullu	☐	☐
Nunaqaqtunut Nunavunmi havagiaktuqtaqpaktunun havaktinut (imaa ujarakhiurviinni)	☐	☐
Aanniarutiqaqtunun *Angiruvit, kaimaluriqtumik naunaiyaqlugit titiqqani ataani* uumanmigut aanniarutpuvangmigut aanniarut kaansaqhimaguvin taqqap tigliit qulvangayut aanniaqtailidjutinun aungani sukaklungniq ajuqhautiqaruvit taqtuklirnirmun aanniaqtailidjutinun tingukliuqtut havautituqtut havautinik tapkua hulaqutigiyaat	☐	☐

Titiqiqiyiinait Atugahaat:

	KAPUUT	NUNAA#	NAYUGAA & AULAVIA	KAPUQHIKTIA & QANGA Atia humungaujuq/Ublua ubluqhiutaa
Hivuliq paaq Kapuqhirvia	**0.3 ml**			**Atia:** **Ublua:** *(dd /Month / yyyy* **Ubluqhiutaa:**
Tugliq Kapuqhirutaa	**0.3 ml**			**Atia** **Ublua:** *dd /Month / yyyy* **Ubluqhiutaa:**
Pingahua Kapuut	**0.3 ml**			**Atia:** **Ublua:** *dd/Month/yyyy* **Ubluqhiutaa:**
Ikajuutikhaq	**0.3 ml**			**Atia:** **Ublua:** *dd/Tatqiqhiutaa/yyyy* **Ubluqhiutaa:**

Uqarumajatit:

ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Formulaire de consentement pour le vaccin COMIRNATY® de Pfizer-BioNTech contre la COVID-19

Veuillez remplir ou mettre une étiquette :

Nom de famille___________________________

Prénom___________________________

Collectivité___________________________

Date de naissance (jj/mm/aaaa)_________________

Veuillez vous assurer que le nom, la collectivité et la date de naissance sont indiqués ci-dessus.

Nº de carte santé (si vous le connaissez) : ___________ **Numéro de la maison (facultatif) :** _________________

Nº de téléphone : ________________________ **Adresse courriel (facultatif) :** __________________

Genre : Homme ☐ Femme ☐ Préfère s'auto-identifier ☐ _________ **Âge :** _____________

Coordonnées du parent/tuteur :

Nom :______________________________**Téléphone :**______________________________________

Si vous êtes la personne qui reçoit le vaccin, veuillez répondre :

S'agit-il de votre première, deuxième ou troisième dose du vaccin Pfizer? ☐1ere ☐2e ☐ 3e ☐vaccin de rappel
***La 3e dose n'est disponible que pour les personnes présentant un déficit immunitaire modéré à sévère. Pour connaître les critères d'admissibilité, veuillez consulter le protocole Comirnaty® de Pfizer-BioNTech au Nunavut.
S'il s'agit d'une deuxième, d'une troisième dose ou d'une dose de rappel, quelle est la date de votre dose précédente? ______ *jour/mois/année* ________

		Oui	Non
1.	**Vous sentez-vous malade et avez-vous de la fièvre aujourd'hui?** (Si oui, veuillez fournir des détails ci-dessous.)	☐	☐
2.	**Est-ce que vous ou votre enfant avez eu la COVID-19?** (Si oui, veuillez indiquer ci-dessous quand les symptômes ont commencé.) *Vous pouvez toujours recevoir le vaccin si vous avez déjà eu ou pensez avoir déjà eu la COVID-19.*	☐	☐
3.	**Êtes-vous, ou pourriez-vous être enceinte?** (Le vaccin vous sera toujours offert.)	☐	☐
4.	**S'il s'agit de votre deuxième, troisième dose ou dose de rappel, avez-vous eu des effets secondaires après les doses précédentes?** (Si oui, veuillez fournir des détails ci-dessous.)	☐	☐
5.	**Avez-vous des problèmes de système immunitaire ou prenez-vous des médicaments qui peuvent affecter votre système immunitaire (par exemple, des stéroïdes à forte dose, la chimiothérapie)?** (Si oui, veuillez fournir des détails ci-dessous.)	☐	☐
6.	**Souffrez-vous d'un trouble hémorragique ou prenez-vous des médicaments qui pourraient affecter la coagulation du sang?** (Si oui, veuillez fournir des détails ci-dessous.)	☐	☐
7.	**Avez-vous déjà eu une réaction grave à un vaccin dans le passé?** (Si oui, veuillez fournir des détails ci-dessous.)	☐	☐
8.	**Êtes-vous allergique au polyéthylène glycol (PEG)**, qui est un ingrédient du vaccin?**	☐	☐
9.	**Avez-vous déjà eu une réaction allergique grave pour laquelle on vous a prescrit un EpiPen?** (Si oui, veuillez fournir des détails ci-dessous.)	☐	☐
10.	**Avez-vous déjà reçu un diagnostic de myocardite ou de péricardite**** suite à l'administration d'un vaccin contre la COVID-19?** (Si c'est le cas, veuillez ne pas procéder à la vaccination aujourd'hui.)	☐	☐

** Le polyéthylène glycol (PEG) peut rarement provoquer des réactions allergiques et se retrouve dans des produits tels que les médicaments, les produits de préparation intestinale pour la coloscopie, les laxatifs, les sirops contre la toux, les cosmétiques, les crèmes pour la peau, les produits médicaux utilisés sur la peau et pendant les opérations, le dentifrice, les lentilles de contact et la solution pour lentilles de contact.

**** De très rares cas de myocardite et de péricardite après une injection de vaccins à ARNm ont été signalés. Les données à court terme suggèrent que ces cas disparaissent d'eux-mêmes chez les patients et patientes et la décision de continuer à administrer un vaccin COVID-19 en cas d'antécédents de myocardite ou de péricardite devrait être prise par le bureau de l'administrateur en chef de la santé publique.

ᐊᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Formulaire de consentement pour le vaccin COMIRNATY® de Pfizer-BioNTech contre la COVID-19

Veuillez remplir ou mettre une étiquette :

Nom de famille___________________________

Prénom___________________________

Collectivité___________________________

Date de naissance (jj/mm/aaaa)_________________

Commentaires des questions ci-dessus :

CONSENTEMENT POUR LE VACCIN PFIZER CONTRE LA COVID-19 :

Pour des informations complémentaires concernant les mineurs matures, veuillez consulter l'annexe C et la section 3.2.3 du Guide d'immunisation du Nunavut.

- Je comprends les informations contenues dans la fiche d'information sur le vaccin Comirnaty de Pfizer-BioNTech contre la COVID-19.
- Je comprends les bienfaits et les réactions possibles du vaccin de Pfizer-BioNTech contre la COVID-19 et le risque de ne pas être vacciné.
- J'ai eu l'occasion de poser des questions et d'obtenir des réponses satisfaisantes.
- Je consens à ce que le vaccin de Pfizer-BioNTech soit administré à : Mon enfant, ☐ Mon enfant en tutelle ☐ ou Moi-même ☐

____

Nom en caractères d'imprimerie **Signature du client/parent/tuteur** **Date (jj/mm/aaa)**

Questions supplémentaires pour aider à comprendre les populations qui reçoivent le vaccin

Groupe à risque *Cochez toutes les cases qui s'appliquent*

	Oui	Non
Je vis dans un centre pour personnes âgées.	☐	☐
Je travaille dans un centre pour personnes âgées.	☐	☐
Je suis un travailleur de la santé.	☐	☐
Je vis dans un foyer d'accueil.	☐	☐
Je vis dans un établissement correctionnel.	☐	☐
Je travaille dans un foyer d'accueil ou un établissement correctionnel.	☐	☐
Je suis âgé de 55 ans ou plus.	☐	☐
Je suis un travailleur en rotation résident du Nunavut (par exemple dans les mines).	☐	☐
Je souffre d'une pathologie sous-jacente. *Si oui, encerclez toutes les réponses applicables dans la liste ci-dessous.* Maladie du cœur · Maladie pulmonaire · Cancer Hypertension artérielle · Diabète · Problèmes avec votre système immunitaire Maladie rénale · Maladie du foie · Prise de médicaments qui affectent le système immunitaire	☐	☐

ᐊᓂᕆᐊᖅᑲᓇᖏᓪᓗᑎᒃᓴᖅᑐᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Formulaire de consentement pour le vaccin COMIRNATY® de Pfizer-BioNTech contre la COVID-19

Veuillez remplir ou mettre une étiquette :

Nom de famille___________________________

Prénom___________________________

Collectivité___________________________

Date de naissance (jj/mm/aaaa)_________________

À l'usage interne seulement :

	DOSE	N^{O} DE LOT :	SITE ET ROUTE	DONNÉ PAR ET QUAND Nom et désignation/Date et heure
1ere dose	**0,3 ml**			**Nom :**
				Date : jj/mois/aaaa **Heure :**
2e dose	**0,3 ml**			**Nom**
				Date : jj/mois/aaaa **Heure :**
3e dose	**0,3 ml**			**Nom :**
				Date : jj/mois/aaaa____**Heure :**
Vaccin de rappel	**0,3 ml**			**Nom :**
				Date : jj/mois/aaaa____**Heure :**

Commentaires :

Information Sheet

COMIRNATY® Pfizer-BioNTech COVID-19 Vaccine

Please read this information sheet carefully and ensure you have a chance to ask a healthcare provider your questions before receiving the vaccine.

If you have symptoms of COVID-19, please do not come into the clinic and call the hotline (1-888-975-8601) to see if you need testing

What is COVID-19?

COVID-19 is an illness caused by a coronavirus, a type of virus. COVID-19 was first identified in late 2019 and declared a global pandemic in early 2020.

COVID-19 is most commonly spread by an infected person to others through coughing, sneezing, talking, singing or breathing. Someone with COVID-19 may not have any symptoms and not know they have COVID-19, but still be able to infect others.

For most people, symptoms of COVID-19 are similar to other respiratory illnesses like the flu or common cold. A smaller number of people with COVID-19 can develop much more severe symptoms requiring hospitalization and it may result in long term side effects or even death.

Who should get the COMIRNATY® Pfizer-BioNTech vaccine against COVID-19?

The COMIRNATY® Pfizer-BioNTech vaccine is free and available to all Nunavummiut over the age of 12. It is up to you whether you decide to get the vaccine for yourself or your child. **It is important to know that you cannot get COVID-19 infection from the vaccine.**

The COMIRNATY® Pfizer-BioNTech vaccine causes our body to produce protection against infection from COVID-19. It is a type of vaccine that uses messenger RNA (mRNA) to help our body make protective antibodies against the virus.

Studies have shown that the COMIRNATY® Pfizer-BioNTech vaccine is very effective. It is important to ensure you complete the vaccine series. The final dose assures long term protection. Even adults who had, or think they might have had, COVID-19 will be offered the vaccine as it will provide additional protection.

Can children be vaccinated?

The COMIRNATY® Pfizer-BioNTech vaccine is only authorized for use in people aged 12 years and older. Younger age groups are likely to have vaccines available in the near future.

You might <u>not</u> be vaccinated today if:

- You have been told you are allergic to one of the components of the vaccine.
- You had a serious allergic reaction to your first dose of COVID-19 vaccine.

If you are pregnant:

- You will have the opportunity to discuss vaccination with a nurse or doctor. **It is up to you whether or not you are vaccinated.**
- COMIRNATY®Pfizer-BioNtech vaccine is safe and effective for pregnant people.

How safe is the COMIRNATY® Pfizer-BioNTech vaccine?

Canada has one of the most rigorous vaccine approval systems in the world. During vaccine development, studies provide information on the safety of a vaccine as well as how effective it is in developing immunity.

What are the side effects of the COMIRNATY® Pfizer-BioNTech vaccine?

The most common side effects that people get after the COMIRNATY® Pfizer-BioNTech vaccine are minor and include:

- Pain, redness or swelling where the needle was given Fatigue, headache, muscle pain, joint pain, nausea/vomiting, fever and chills. All of these side effects usually disappear within 1-3 days without treatment. If they do not go away, call the health centre.

Serious side effects such as an extreme allergic reaction are very rare. Symptoms of an allergic reaction include hives (bumps on the skin that are often very itchy), swelling of your face, tongue or throat, or difficulty breathing.

The clinic staff are prepared to manage an allergic reaction should it occur and will provide immediate medical care if you develop any of these symptoms.

COVID-19 Vaccine After Care Sheet

What should I do right after receiving the COVID-19 vaccine?

- **Everyone must wait for at least 15 minutes** in the clinic after receiving their vaccine.
- Longer waiting times of 30 minutes may be recommended if there is concern about a possible vaccine allergy.
- Although they are uncommon, allergic reactions may occur.
- Symptoms of an allergic reaction include:
  - Rash or bumps on the skin that are often very itchy (also called hives);
  - Swelling of the face, tongue or throat;
  - Difficulty breathing.
- Let one of the staff at the clinic know if you or your child feel unwell while waiting.
- If you or your child feel unwell, please do not leave the building.

What should I expect in the next few days?

- Side effects may develop the day after you receive the vaccine and will usually go away on their own a day or two later**.**
  - Pain, swelling or redness where the needle was given are the most common side effects. A cool, damp cloth or ice pack wrapped in cloth may help.
  - Tiredness, headache, muscle pain, joint pain, nausea, vomiting, chills or fever may occur.
  - Swollen glands in your underarm are another possible side effect.
- If needed, pain or fever medication (such as Tylenol or Advil) may help with pain or fever. Make sure to follow the instructions on the label and check with your health care provider if you need advice about medication.
- Serious side effects after receiving the vaccine are extremely rare - if you have any concerns about the symptoms you develop after receiving the vaccine, contact the Health Centre for advice.

Things to remember:

- The COVID-19 vaccines used in Nunavut are 2or 3-dose vaccines. Ask your healthcare provider when you should return for your second or third dose.
- Continue to follow recommendations to prevent the spread of COVID-19 including careful handwashing, staying at least 2 metres from others, and limiting / avoiding contact with others outside of your household.
- Tell the person providing the second dose if you had any side effects with your first dose.

Vaccin contre la COVID – Fiche de suivi

Que dois-je faire juste après avoir reçu le vaccin contre la COVID-19?

- **Tout le monde doit attendre au moins 15 minutes** dans la clinique après avoir reçu son vaccin.
- Des temps d'attente plus longs, de 30 minutes, peuvent être recommandés si l'on craint une éventuelle allergie au vaccin.
- Bien qu'elles soient peu fréquentes, des réactions allergiques peuvent se produire.
- Les symptômes d'une réaction allergique sont les suivants :
  - Éruption ou bosses sur la peau qui provoquent souvent de fortes démangeaisons (également appelées urticaire);
  - Gonflement du visage, de la langue ou de la gorge;
  - Difficulté à respirer.
- Faites savoir à l'un des membres du personnel de la clinique si vous ou votre enfant ne vous sentez pas bien pendant l'attente.
- Si vous ou votre enfant ne vous sentez pas bien, veuillez ne pas quitter le bâtiment.

À quoi dois-je m'attendre dans les prochains jours?

- Les effets secondaires peuvent apparaitre le lendemain de la vaccination et disparaissent généralement d'eux-mêmes un jour ou deux plus tard.
  - Des douleurs, des gonflements ou des rougeurs à l'endroit où l'aiguille a été administrée sont les effets secondaires les plus fréquents. Un chiffon frais et humide ou une poche de glace enveloppée dans un tissu peut aider.
  - De la fatigue, des maux de tête, des douleurs musculaires, des douleurs articulaires, des nausées, des vomissements, des frissons ou de la fièvre peuvent survenir.
  - Le gonflement des glandes sous les aisselles est un autre effet secondaire possible.
- Si nécessaire, des médicaments contre la douleur ou la fièvre (tels que Tylenol ou Advil) peuvent aider à soulager la douleur ou la fièvre. Veillez à suivre les instructions figurant sur l'étiquette et consultez votre prestataire de soins de santé si vous avez besoin de conseils sur les médicaments.
- Des effets secondaires graves après avoir reçu le vaccin sont extrêmement rares. Si vous avez des inquiétudes concernant les symptômes que vous présentez après avoir reçu le vaccin, contactez le centre de santé pour obtenir des conseils.
- Si vous présentez des symptômes comme des douleurs thoraciques, une oppression thoracique ou des palpitations cardiaques, communiquez immédiatement avec votre fournisseur de soins de santé.

Vaccin contre la COVID – Fiche de suivi

Ce qu'il faut retenir :

- Les vaccins contre la COVID-19 utilisés au Nunavut sont des vaccins à deux ou trois doses. Renseignez-vous auprès de votre prestataire de soins pour connaitre la date à laquelle vous devez revenir pour recevoir votre deuxième ou troisième dose.
- Continuez à suivre les recommandations visant à prévenir la propagation de la COVID-19, notamment en vous lavant soigneusement les mains, en vous tenant à au moins 2 mètres des autres et en limitant/évitant tout contact avec des personnes extérieures à votre foyer.
- Informez la personne qui vous a administré la deuxième ou troisième dose si vous avez eu des effets secondaires lors de la première dose.

COVID-19 Qalagjuarnikkut Kapuutimin –

Hulijukhauvinga kapurhiqtauhuiruma uuminnga COVID-19 qalagjuarnikkut kapuutimik?

- **Tamaita utaqqijukhat ikinikhaanun 15nik minitsinik** munarhitkunni kapurhiruirumik.
- Takitqijat utaqqivighat imaatun 30nik minitsinik pitqujauttaaqtun ihumaaluutiqaqqat piniaqtaarungnarhijunik kapuutimin nakuuhuirutinik (allergy) kinamun.
- Piqattajuitkaluarhutik, kapuutimin nakuuhuirutit qanurilidjutit (allergic) pittaaqtun.
- Naunaitkutit qanurilidjutini nakuuhuirnikkut (allergic) ilaqaqtun:
    - Aupadjangniq puvinniilluunniit uviningmi kukulaqiqpiarhimajun (taijauvaktullu hives-nik)
    - Puvinniq akuliami, uqarmi iggiarmiluunniit;
    - Ajurhaliruvit anirhaaktariami.
- Ilitturipkarlugin havaktiit munarhitkunni nakuuhuiruvin nutaralluunniit utaqqitillutin.
- Nakuuhuiruvin nutaralluunniit, qimaktailugu munarhitkut.

Hunat niriuktakhatka tikittukhani ikittuni ubluni?

- Kapuutimin hulaqutit pittaaqtun aqagunguqqat kapuqtauhimavingnirnin tammainnaqpaktullu ingmingnik atauhirmi malruungniluunniit ubluni.
    - Ulurianarniq, puvinniq aupadjangniqluunniit kapijauvingmi pillualiqpaktun hulaqutit. Niglaumajuq, qinipajuq allarun unaluunniit hiku puuqtauhimauuq allarutimi ikajuutijaaqtun.
    - Unaguhungniq, niaqurliurniq, nukiinni ulurianarniq, ipiringnirniinni ulurianarniq, mirianguniq, miriarniq, qaalin'nguhungniq kidjangniqluunniit pittaaqtun.
    - Puvihimajun qinirhinat unirhukni pijaaqturlu hulaquti.
- Ihariagigungni, ulurianarnirnun kidjangnirnulluunniit havautit (imaatun Tylenol unaluunniit Advil) ikajuutauttaaqtun ulugiarnarnirnun kidjangnarnulluunniit. Maliklugin maliqujaujun titiraani uqaqatigilugulu munarhi uqaujjijaujumaguvin havautikkut.
- Qajangnaqtut hulaqutit kinguagun kapurhirnirmin pilluajuitpiaqtun - qujaginnaq ihumaaluutiqaruvin ukunani naunaitkutinik piliqtunik kinguagun kapurhirnirnin, hivajadjavan Munarhitkut uqaudjutikhanun.
- Piqarliruvin naunaitkutinik ilaujullu hatqarmi uluhianarhijumik, hatqarmi hukahimalrnirmik, uummatilluunniit hajulaqikpat uqaqatigijakhat munarhitkut qilamik.

COVID-19 Qalagjuarnikkut Kapuutimin –

Hunat itqaumajakhat:

- Ukuat COVID-19 qalagjuarnirmun kapurutit atuqtaujun Nunavunmi hapkuangujun malruuk (2) pingahulluunniit-havauhikkut (3) kapurutit. Apirilugu munarhigijat qakugu utiqtukhauguvin pijaami tuklirnik pingahuanikluunniit kapurhirutikharnik.
- Maliqqahimmaarlugin pitqujauhimajun hiamitiqtailinikkut COVID-19 Qalagjuarnirmik ilaujullu algangnik-uaqtiarnirnik, ahiqpaniinnirniklu 2 miitanik aallanin, kikliqaqtirniq / akturuirlugillu aallat iglumiutaqatigingitatin.
- Unniutilugu inuk kapihiniarhimajuq tukliqmik pingahuanikluunniit kapuutikhamik pihimavakkuvin qujaginnanik qanuqtun hulaqutinik talvannga hivulliqpaarnin kapuqtauhimavingnin.

ᓄᕗᒡᔪᐊᕐᓇᖅ-19ᒧ ᐋᓐᓂᐊᓕᓅᒃᑯᑎ ᑲᒪᒋᔭᐅᕌᓂᒃᑐᓄᑦ ᑐᓴᐅᒪᑎᑦᑎᔾᔪᑎ

ᖃᓅᔭᕆᐊᖃᖅᐳᖓ ᑲᐱᔭᐅᕌᓂᒃᑯᒪ ᓄᕙᕐᔪᐊᕐᓇᖅᗏᖅᑕᐃᓕᒪᔾᔪᑎᒥᒃ?

- **ᐃᓄᓕᒫᑦ ᑕᒪᐃᓐᓂᒃ ᐅᑕᖅᑭᔭᕆᐊᓖᑦ 15 ᑎᑦᑕᑯᓗᖕᓂᒃ ᑕᕝᕙᓂ ᐋᓐᓂᐊᕕᖕᒥ ᑲᐱᔭᐅᕝᕕᒋᔭᕐᓂᒃ ᐅᑕᖅᑭᔭᕆᐊᖃᖅᑐᑎᑦ ᑲᐱᔭᐅᕌᓂᒃᓯᒪᓕᕈᕕᑦ.**
- ᐊᑯᓂᐅᓂᖅᓴᖅ ᐅᑕᖅᑭᖁᔭᐅᑐᐃᓐᓇᕆᐊᖃᖅᑐᑎᑦ ᓲᕐᓗ 30–ᓂᒃ ᑎᑦᑕᑯᓗᖕᓂᒃ ᑎᒫᑦ ᑭᓱᓂᒃ ᐱᐅᒃᓴᙱᓐᓂᕐᒧᑦ ᖃᓄᐃᔾᔪᑎᖃᖃᑦᑕᕈᕕᑦ.
- ᑕᐃᒪᐃᑦᑐᖃᕆᔾᙱᒃᑲᓗᐊᖅᑎᓪᓗᒍᓕ, ᑎᒥ ᐱᐅᒃᓴᙱᓐᓂᖕᖓᓄᑦ ᖃᓄᐃᑦᑐᖃᓕᑳᓪᓚᒍᓐᓇᕐᒪᑦ.
- ᑲᐱᔭᐅᕌᓂᒃᑐᑦ ᑎᒥᖕᒋᑦᑎᒍᑦ ᓈᒻᒪᙱᓪᓕᐅᕈᑕᐅᓲᑦ ᒪᑯᐊᖑᕗᑦ:
  - ᐅᕕᓂᐊᒍᑦ ᖃᑦᑎᒐᖀᓕᖅᓘᑎᒃ ᐅᖏᓚᒃᑑᓪᓗᑎᒃ (ᑕᐃᔭᐅᕙᖕᒥᔪᖅ ᐱᖑᔭᖕᓂᖅ);
  - ᑮᓇᒃᑯᑦ ᐳᕕᓕᖅᓘᑎᒃ, ᐅᖃᒃᑯᑦ ᐅᕝᕙᓅᓐᓂᑦ ᐃᒋᐊᒃᑯᑦ;
  - ᐊᓂᕐᓂᑭᓪᓗᓂ
- ᐃᖅᑲᓇᐃᔭᖅᑐᒥᒃ ᐅᖃᐅᔾᔨᓗᑎᑦ ᐃᔪᕐᓇᙱᑦᑑᓕᑐᐊᕈᕕᑦ ᐅᑕᖅᑭᓂᕐᓂᒃ.
- ᓇᖕᒥᓂᖅ ᕿᑐᙳᕆᓇᔭᐃᓪᔫᓃᑦ ᐃᔪᕐᓇᔪᓐᓃᕈᓯ ᐊᓂᑦᑕᐃᓕᒋᑦᑎ ᑲᐱᔭᐅᕝᕕᒋᔭᔅᓯᓐᓂᒃ.

ᖃᓄᕐᓕ ᑕᐃᒪ ᓂᕆᐅᒍᓐᓇᕐᓂᐊᖅᐳᖓ ᐅᓪᓗᓂᒃ ᐊᒃᑎᖅᑐᓂ?

- ᑲᐱᔭᐅᕌᓂᒃᓯᒪᓕᖅᑎᓪᓗᑎᑦ ᐃᒃᐱᒍᓱᑲᑕᓚᐅᑲᖕᓂᐊᖅᑐᒃᓴᐅᔪᑎᑦ ᐅᓪᓗᐃᓐᓇᕐᒥᐅᕙᓗᐊᖅ ᑭᓱᐊᓂᓕ
-

- ᖃᐅᓯᒪᓕᖅᐸᑦ ᐃᒃᐱᖕᓇᕈᓐᓃᓪᓗᐊᖅᑐᖅ ᑲᐸᕐᓯᕆᓂᕆᔭᐃᑦ.
  - ᐋᓐᓂᐊᓕᕐᓗᓂ, ᐳᕕᓕᕐᓗᓂ ᐊᐅᐸᖅᓯᓗᓂᓘᓃᑦ ᑲᐱᔭᐅᕝᕕᒋᔭᐃᑦ ᐃᒃᐱᒋᔭᐅᑲᐅᑎᒋᔪᙶᔪᑦ ᑭᓯᑐᐃᓐᓇᕐᒧᑦ ᑲᐱᔭᐅᔪᐃᑦ. ᓂᒡᓕᓇᖅᑐᒥᒃ, ᖃᐅᓯᕐᓗᓂ ᐊᓪᓚᕈᑎᑯᓗᖕᒧᑦ ᐸᑎᒻᒥᒍᕕᐅᒃ ᐃᑲᔫᑎᖃᕈᓇᕐᒥᔪᖅ.
  - ᑎᒥᒃᑯᑦ ᑕᖃᖓᓗᓂ, ᓂᐊᕐᑯᓕᖓᓗᓂ, ᓄᑭᑎᑦ ᐋᓐᓂᐊᕐᓗᑎᒃ, ᓇᒡᒍᐊᑎᑦ ᐃᒃᐱᖕᓇᕐᓗᑎᒃ, ᒥᕆᐊᙳᓗᑎᑦ, ᒥᕆᐊᖅᓴᑲᑕᒡᓗᑎᑦ, ᕿᐅᓕᖅᐸᒡᓗᑎᑦ ᐅᕝᕙᓘᓐᓂᑦ ᐆᑎᕐᓇᖅᓯᑲᑕᑐᐃᓐᓇᕆᐊᖃᕆᕗᑎᑦ.
  - ᐅᓂᒃᑯᑦ ᕿᓕᖅᓯᓇᖅ ᐳᓕᑐᐃᓐᓇᕆᐊᖃᕐᒥᔪᖅᑕᐅᖅ.
- ᐱᔭᕆᐊᖃᕈᕕᑦ, ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔾᔪᑎᒥᒃ ᓂᐊᕐᑯᖅᓯᐅᑎᒥᒡᔫᓃᑦ (ᑕᐃᓕᓈᓕᒥᒃ ᐋᕕᐅᓕᒥᒡᔫᓃᑦ) ᐋᓐᓂᐊᕈᓐᓃᖅᐹᓪᓕᕐᓇᖅᑐᖅ ᐆᑎᕐᓇᕈᓐᓃᖅᐹᓪᓕᕐᓇᖅᑐᓂᓗ. ᖃᓅᔭᕆᐊᖃᕐᓂᕋᐃᔪᑦ ᒪᓕᑦᑎᐊᕐᓂᐊᖅᐸᑎᑦ ᐊᒻᒪ ᐋᓐᓂᐊᓯᐅᖅᑎᒋᔭᕐᓄᑦ ᑐᑭᓯᒋᐊᒃᑲᓐᓂᖅᐸᓪᓗᑎᑦ ᐃᓅᓕᓴᐅᑏᑦ ᒥᒃᓵᓄᑦ.
- ᐊᑦᑕᕐᓇᖅᓯᔪᕐᑲᓗᐊᖅᐸᙱᑦᑑᒐᓗᐊᖅ ᑲᐱᔭᐅᕌᓂᒃᑐᕕᓂᕐᒥᒃ – ᐃᓱᒫᓘᑎᖃᑐᐊᕈᕕᑦ ᑲᐱᔭᐅᕌᓂᒃᓯᒪᓕᕐᓗᑎᑦ ᖃᓄᐃᔾᔪᑎᒋᔭᕐᓄᑦ, ᐋᓐᓂᐊᕕᖕᒧᑦ ᑐᑭᓯᒋᐊᒃᑲᓐᓂᕐᓗᑎᑦ.
- ᖃᓂᒪᒃᑳᓪᓚᒃᑯᕕᑦ ᐱᖃᓯᐅᑎᓗᒍ ᖁᖅᑲᓕᕈᕕᑦ, ᐊᓂᖅᑎᓇᓗᐊᓕᕈᕕᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐆᒻᒪᓯᕆᓕᕈᕕᑦ ᐋᓐᓂᐊᓯᐅᖅᑎ ᖃᐅᔨᒋᐊᑲᐅᑎᒋᓗᒍ.

ᓄᕙᒡᔪᐊᕐᓇᖅ-19ᒧ ᐋᓐᓂᐊᓕᕆᒃᑯᑎ ᑲᒪᒋᔭᐅᕌᓂᒃᑐᓄᑦ ᑐᓴᐅᒪᑎᑦᑎᔾᔪᑎ

ᐃᖅᑲᐅᔭᕆᐊᖅᑕᖅᑕᑎᑦ:

- ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᕇᒃᑯᑎᒧᑦ ᑲᐱᔭᐅᓗᓂ ᓄᓇᕗᒻᒥ ᒪᕿᐃᖅᑕᐅᓲᖅ ᐅᑲᕙᓘᓃᑦ ᐱᖓᓱᐃᓱᖅᑕᐅᓪᓗᑎᒃ. ᑲᐱᓯᔨᒋᔭᐃᑦ ᐋᓐᓂᐊᓯᐅᖅᑎᒥᒡᓘᓃᑦ ᐊᐱᕆᓂᐊᖅᐳᑎᑦ ᖃᖓ ᐅᑎᕆᐊᖃᕐᒪᖔᕐᓂᒃ ᑭᖑᓪᓕᐊᓄᑦ ᐱᖓᔪᖓᓄᓪᓘᓐᓃᑦ ᑲᐱᔭᐅᕖᒃᓴᕐᓄᑦ.
- ᐊᑐᕐᑯᔭᐅᔪᑦ ᐊᐃᑦᑐᕐᓗᐃᑦᑕᐃᓕᒪᓂᕐᒧᑦ ᓄᕙᕐᔪᐊᕐᓇᖅ-19–ᒥ ᒪᓖᓐᓇᕐᓗᒋᑦ ᓲᕐᓗ ᒪᑯᐊ ᐊᒃᓯᑎᑦ ᓴᓗᒪᑎᓪᓗᒋᑦ, 2 ᒦᑕᓂᒃ ᐅᖓᓯᒃᓴᐃᓐᓇᕐᓗᑎᑦ ᐃᓅᖅᑲᑎᖕᓂᒃ, ᐃᓄᖕᓂᒃ ᑲᑎᙵᓗᐊᖅᑕᑦᑕᙱᓪᓗᑎᑦ/ᐅᐸᒃᓯᓯᒪᓗᐊᙱᓪᓗᑎᓪᓗ ᐃᒡᓗᕕᑦ ᓯᓚᖀᓂ.
- ᑭᖑᓪᓕᕐᒥ ᑲᐱᔭᐅᓕᖅᑎᓪᓗᑎᑦ ᑲᐱᓯᒧᖅ ᐅᖅᑲᐅᑎᓗᒍ ᖃᓄᐃᔾᔪᑎᖃᓛᐅᑐᐊᕈᕕᑦ ᓯᕗᓪᓕᕐᒥ ᑲᐱᔭᐅᑎᓪᓗᑎᑦ.

Appendix B COVID-19 Vaccine Protocol

Guidance for Vaccination with COVID-19 Vaccines During a Home Visit

Background:

There are several reasons a small number of individuals may not be able to come to the Health Centre or Clinic to be vaccinated and may need to receive the COVID-19 vaccine at home. While every effort should be made for clients to travel to the clinic for their immunization, there will be circumstances where this is just not feasible. The purpose of this document is to outline a procedure to bring the vaccine to these clients in a home visit in a way which ensures:

- The vaccine is transported in a way which maintains its effectiveness when administered.
- Wastage of the vaccine resulting from the home visit is as limited as possible.

Note that COVID-19 vaccines are more unstable than most other vaccines currently in use and there is concern that jarring or shaking the vaccine, would make the vaccine less effective or ineffective. Frozen transport is preferred to any liquid/thawed transport. **Do not transport pre-filled syringes or punctured/diluted vials.**

Preparing for a home visit:

Please note that COVID-19 vaccines are more unstable than most other vaccines currently in use and is recommended to be transported in a frozen state and then thawed (please see appropriate thawing guidance in the SPIKEVAX® and COMIRNATY® COVID-19 immunization protocols as they are unique for both vaccines).

The risk of transporting the vaccine in a liquid, thawed state is that any jarring or shaking, even from going over a gravel road in a car, would render the vaccine ineffective and not protect the vaccinated client from COVID-19 infection so frozen is the preferred option.

The following steps should take place at least a day before the home visit is planned:

Identifying Health Care Providers:

- Two healthcare staff are to attend the home visit, including an interpreter if required. If only one nurse is available to attend, a second attendant must accompany in case any urgent situations arise.

Identifying clients:

- Home care clients should be carefully screened to identify individuals who cannot access the clinic. All options to assist the client to attend the clinic should be explored before making plans for a home visit. This could include doing a radio call out for volunteers to drive clients who require assistance to the clinic.
- Once a client has been identified for home visit - explore with the client and family if anyone else in the house is eligible to receive the vaccine. Consideration should be given to vaccinating anyone in the household who is eligible to reduce wastage of vaccine by using all doses in the vial. Please review eligibility requirements in the appropriate COVID-19 immunization protocol.
- If the community has an Elder's apartment complex (These are self-contained / separate apartments) and there is one Elder who cannot reasonably travel to the clinic, consider offering vaccination to all Elders living in those apartments at the same time to minimize wastage / doses discarded.

Obtaining consent:

- When clients are identified, make arrangements to conduct a home visit, with an interpreter if required, to obtain their informed consent for the vaccine. You will need to take both the consent Forms and Information Sheets to this visit. The consent Forms are brought back to the Health Centre and the Information Sheet left with the client.
- If possible, obtain consent, in advance, from other eligible family members, other household contacts or others in the apartment building at the same time. This helps to confirm there will be 10 people willing to be vaccinated during the same visit. While this is a time-consuming process, it will reduce vaccine wastage.
- Note that this step may be combined with the visit itself in some circumstances. At minimum, verbal consent should be obtained prior to the home visit.

Making appointments:

- At the visit to obtain consent, provide an appointment card. Alternatively, advise the client they will be contacted by the health centre to confirm the appointment date and time.
- Inform the client and family in advance that the healthcare team may be at the home for longer than one hour, to allow required thawing time. Reminder: thawed vials cannot be moved between households.

Securing vaccine:

- Notify the person in charge of ordering the vaccine that a vial will be required for vaccinations during a home visit so that a vial will be available on that day.

- Refrigeration packs for transporting the vaccine are to be assembled with the cooling packs placed in the freezer or fridge. For any inquiries related to vaccine transport, please contact your regional pharmacy or the COVID-19 Special Operations Division.

On the day of the home visit:

- The morning of the home visit, the clerk is to contact the client to:
    - Confirm the time for the home visit.
    - Confirm that the client and household members are still wanting to receive vaccine.
    - Screen for any symptoms of acute or febrile illness using the COVID-19 Vaccine Clinic Screening Questionnaire.
    - Confirm all individuals eligible for the vaccine are booked and registered on Meditech.
- The clerk should notify the nurse of any concerns prior to the visit.
- Gather supplies (see list below) and assemble the transportation refrigeration pack (see Appendix A for details on assembling pack).
- The frozen or fridge temperature vial will be signed out to indicate it is being used for a home visit. A Vaccine Vial Tracking Log will need to accompany the vaccine. The vial should not be taken out of the freezer or fridge and put into the refrigeration pack until the health care team are ready to leave the health centre. **Do not transport pre-filled syringes or punctured/diluted vials.**
- **The refrigeration cooler with the vial should be held in the hands or on the lap of one of the immunizers during transport. The cooler is not to be put on the floor or in the trunk of a car. Every attempt should be made to carry the cooler without jostling.**
- The vial is transported back to the clinic in the cooler to be discarded; any wastage is recorded on the Vaccine Vial Tracking Log. NOTE: Any remaining doses in a punctured vial should not be used after transport.

Materials Needed to Administer the Vaccine (non-outbreak community):

Patient's file and immunization record cannot leave the health centre but should be reviewed prior to the home visit.

☐ Cell phone	☐ Vaccination record wallet card
☐ Anaphylaxis kit – (Appendix B)	☐ Completed Consent Forms
☐ Cooler with frozen packs and vaccine (Appendix A).	☐ Spare Consent Forms and Information Sheets in appropriate languages
☐ Surgical masks (for providers, client and household members)	☐ After Care sheets in appropriate languages
☐ Disposable face shield or goggles	☐ Reporting Adverse Event Forms
☐ Hand sanitizer	☐ Vaccine Log
☐ Cotton balls or gauze pads	☐ Blue pad
☐ Sterile syringes and needles	☐ Sharps container
☐ Antiseptic swabs	☐ Bag(s) for used materials

Materials Needed to Administer the Vaccine (outbreak community):

- In addition to above materials, the following additional PPE is required:
    - Disposable gown, gloves, booties

During the home visit (non-outbreak community):

1. Just before leaving the clinic, the clerk to call the client and notify them the team is en-route.
2. Don mask before leaving the car; bring masks for household members.
3. Remove outerwear and don face shield (or goggles) immediately upon entering the home..
4. Ask the clients and others in the home to also don a mask.
5. Sanitize hands, put a blue pad down on a surface to create a clean field and remove the frozen vial from the refrigerated container, marking the time the vaccine is removed on the Vaccine Vial Tracking Log. Record the time the vaccine will be thawed (1 hour later), diluted (if applicable)and when it should be discarded. For patient comfort, the vaccine can be left at room temperature for a further 15min to ensure room temperature and minimize discomfort.
6. While vaccine is thawing, review informed consent a final time in case client has any questions. At this time, also review consents of other household members receiving the vaccine.
7. Place remaining vaccine administration supplies on the clean field. The sharps container and anaphylaxis kit placed nearby and easily accessible.
8. Prepare and administer as per the appropriate COVID-19 Immunization Protocol.
9. Put syringe directly into the sharps container and document vaccine administration on the back of the consent form. Give client the After Care sheet.
10. Stay with the client for at least 15 minutes to ensure there are no adverse reactions; 30 minutes if there are concerns about allergies. Ensure client has a means to contact Health Centre if having a reaction beyond the 15 min wait.
11. Give client their vaccination record wallet card as well as an Appointment Card with a date for the second dose according to the appropriate vaccine protocol. Inform the client the health centre will contact them prior to the next appointment.
12. Collect used materials and take with you in a bag.
13. Perform hand hygiene with hand sanitizer.

During the home visit (outbreak community):

- As above with additional measures to prevent transmission of infection - droplet and contact precautions when visiting the home of a client with suspected COVID19. This includes gown, gloves, booties, surgical mask and face shield.
- Additional resources are available in the Infection Prevention and Control Manual and Housekeeping Manual including posters on donning and doffing PPE.
- In an outbreak community it would be safer to vaccinate household contacts rather than those who live in other households in the same building to reduce the spread of infection. This may mean some vaccine wastage occurs.

Additional Infection Prevention and Control Strategies:

1. Explain to client that you will be using disposable PPE and ask if your disposable PPE can be left in the home for the client to discard. Explain to client that they should maintain at least 2 metres physical distancing while removing PPE.
2. Only carry supplies required to administer vaccine and disposable PPE. Avoid using your cell phone or accessing anything that may be in your pockets.
3. Bring vaccine supplies into the house as described above – in outbreak communities, may wish to wait outside of home for part of the time while vaccine is thawing.

References

Ontario Ministry of Health. (2020). Novel Coronavirus (COVID-19) Guidance for Home and Community Care Providers Retrieved from: http://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/2019_home_community_care_guidance.pdf

Government of Nunavut, Department of Health. Immunization Manual. Retrieved from: https://www.gov.nu.ca/health/information/manuals-guidelines

Appendix A: 3.1.7 Maintaining Cold Chain during Transport

[Note that this guidance is adapted from the Nunavut Immunization Manual and is copied here for convenience. For updates, it is best to check the Immunization Manual.]

The following items are essential for ensuring that cold chain is maintained during transport and when conducting clinics outside of the health centre.

Hard-sided plastic insulated container

Refrigerator-conditioned cold packs

Newer Styrofoam cooler with walls at least 2 inches thick

Vaccines should be packed in layers to prevent shifting of the contents during transport. Be sure to place an insulating barrier between the refrigerated or frozen packs and the vaccines to prevent accidental freezing.

Container for transport

Vaccines should be transported in insulated containers. Soft-sided coolers, thin-walled coolers, and banged-up styrofoam containers should not be used. Please note that Vaccines are double-boxed during the winter months (Oct.1 to May 31)

Cooling Packs

There are two main types of cooling packs: refrigerator-conditioned (refrigerated at +2°C to +8°C) and frozen packs available for packing vaccines. The use of these packs for transporting vaccines will depend on the ambient temperature, the amount and type of vaccine, and the size of the container.

Frozen Packs

Insulating Barrier/Filler Materials and the Vaccine

Packing peanuts

Bubble wrap

Blue pads

Pack vaccines in their original packaging on top of the barrier. Do not remove vaccine vials from individual boxes – if multiple vials are in a single box the vial required for the home visit will need to be removed. Be sure to fill any spaces between vaccine boxes with crumpled paper or other filler to prevent shifting of contents in the insulated container.

Temperature Monitor

Warm/cold markers Min/max thermometer

Use a properly placed min/max thermometer or cold chain monitor near the vaccine. The temperature- monitoring device should be placed in the middle of the vaccines and should not come in contact with the refrigerated or frozen packs.

References:

1. Adapted from Nova Scotia Immunization Manual, by the Government of Nova Scotia, 2008. Adapted with permission.
2. Public Health Agency of Canada (2007). National Vaccine Storage and Handling Guidelines for Immunization Providers [PDF version]. Retrieved from http://www.phac- aspc.gc.ca/publicat/2007/nvshglp-ldemv/pdf/nvshglp-ldemv-eng.pdf.

Appendix B: 3.7.6 Anaphylaxis Management in the Community

[Note that this guidance is adapted from the Nunavut Immunization Manual and is copied here for convenience. For updates, it is best to check the Immunization Manual.]

This section is intended as a guide for the initial management of patients in a mass immunization clinic, public health clinic, or similar non-emergency setting. For severe life-threatening anaphylaxis, advanced care should be managed in the health centre or hospital setting following the protocol outlined in Section D-09 and D-10 of the Government of Nunavut Drug Formulary.

Action of Epinephrine

IM is the preferred route for the administration of epinephrine and the thigh is the preferred site for its administration.

When epinephrine is administered intramuscularly, it acts on beta adrenergic receptors found in the skeletal muscle vasculature causing vasodilation. Thus, when IM immunization is given and epinephrine is indicated, it should not be administered into the same muscle mass as the vaccine was administered. The epinephrine will produce vasodilation locally at the site, increase vascular permeability, and may increase absorption of the offending antigen.

Side effects of excessive doses of epinephrine pose little danger but can add to the person's distress by causing palpitations, tachycardia, flushing, and headache. Cardiac dysrhythmias can occur in older adults but are rare in otherwise healthy children.

Administration of Epinephrine

Call emergency response as per community guidelines.

Administer epinephrine IM immediately. The most important step in the management of anaphylaxis is the immediate administration of aqueous epinephrine 1:1,000. Failure to use epinephrine promptly is more dangerous than its improper use. Use the epinephrine dosing chart outlined in "Anaphylaxis: Initial Management in Non-hospital Setting" in Section 3.7.10.

IM injection of epinephrine into the thigh is the preferred route for administration.

DO NOT inject epinephrine into the same muscle mass (e.g., thigh) as the vaccine was administered.

If the thigh cannot be used in a child ≥ 12 months of age or an adult (e.g., client has received IM injections in both thighs), give epinephrine IM into the deltoid muscle(s).

If both arms and both legs have been used for IM immunizations, administer epinephrine SC into the upper outer triceps area of the arm(s), or into the fatty area of the anterolateral thigh.

Injection of epinephrine can be made through clothing, if necessary.
Repeat epinephrine at 5-minute intervals twice as needed (i.e., if breathing becomes more laboured or level of consciousness decreases). Note: Administer a maximum of three doses of epinephrine.

Alternate between right and left thigh or arm sites for repeat doses of epinephrine (to maximize absorption of epinephrine).

Note: An epinephrine self-injector (Epipen or Twinject) can also be used in the situation when the immunization provider is not present and if the layperson who administers the self-injector is knowledgeable about proper use. The regular preparations contain 0.3 mL of epinephrine 1:1000 and can be used for individuals over 6 years of age. If a vaccinee or their parent/guardian refuses the administration of epinephrine when it is indicated, inform them of the risk and immediately call for help to arrange for transfer to an acute care facility. The administration of diphenhydramine hydrochloride (Benadryl) is not appropriate in this situation. Diphenhydramine hydrochloride is considered second-line therapy to epinephrine and should never be administered alone in the treatment of anaphylaxis.

Diphenhydramine Hydrochloride (Benadryl)

Give one dose of diphenhydramine hydrochloride (Benadryl) IM as an adjunct to epinephrine when the person is not responding well to epinephrine, or to maintain symptom control in those who have responded (as epinephrine is a short-acting agent). Its use is recommended when transfer to an acute care facility cannot be done within 30 minutes. Its use is considered second-line therapy to epinephrine and should never be administered alone in the treatment of anaphylaxis.

The approximate doses for injection (50 mg/ml solution) are outlined in “Anaphylaxis: Initial Management in Non-hospital Setting” in 3.7.10. NOTE: BENADRYL IS PAINFUL WHEN GIVEN IM.

When administering diphenhydramine hydrochloride IM, preferably administer at a different site to that in which epinephrine was given. However, if necessary, give diphenhydramine hydrochloride in the same thigh as that in which epinephrine was given.

Diphenhydramine hydrochloride can be given into the same muscle mass as the vaccine was given.

Diphenhydramine hydrochloride can be given at any time interval either after the initial or repeat doses of epinephrine, as indicated by the person’s condition.

3.7.7 Other Considerations

Position client in the recumbent position and elevate legs, as tolerated symptomatically. This slows progression of circulatory compromise, if present, by preventing orthostatic hypotension and helping to shunt effective circulation from the periphery to the head, heart, and kidneys.

Monitor pulse, respiratory effort, and level of consciousness to guide medication use: • If person experiences respiratory difficulty: elevate head and chest slightly.
• If airway is impaired: improve position by using head tilt, chin lift, or jaw thrust.
• If vomiting is likely, turn person to side lying position.

Arrange for rapid transport by vehicle to the health center or emergency room (depending on community). Since 20% of anaphylaxis episodes follow a biphasic course with recurrence of the reaction after a 2 – 9 hour asymptomatic period, hospitalization or a long period of observation is recommended for monitoring.

3.7.8 Recording of the Anaphylactic Event

Administration of epinephrine and diphenhydramine hydrochloride may be recorded on the "Anaphylaxis Assessment Guide and Record" found in section 3.7.11.

Report the case of anaphylaxis using the Adverse Events Following Immunization (AEFI) form found in Section 3.5.

Document the vaccine reaction on Immunization Record under the comments section.

Await the CPHO review and recommendation regarding subsequent immunization with the associated biological product(s).

If the reaction is deemed to have been anaphylactic, the associated biological product(s) cannot be administered in the future. Except in the case of rabies post-exposure vaccine, the history of anaphylaxis is a contraindication to the administration of the associated biological product(s).

Record this contraindication in the client's personal and electronic immunization record. Discuss with the client/guardian the CPHO recommendation regarding subsequent immunization.

References

- British Columbia Centre for Disease Control Section V –Management of Anaphylaxis in a Non-clinical Setting, by the British Columbia Centre for Disease Control. The materials in this section were adapted and are being used with permission of British Columbia Centre for Disease Control.
- Government of Nunavut, Department of Health. Immunization Manual. Retrieved from: The Immunization Manual (https://gov.nu.ca/health/information/manuals-guidelines)

Nunavut COVID-19 Vaccine Materials & Immunization Protocol

Appendix C. Orientation to Obtaining Consent for Administration of COVID-19 Vaccines

Introduction:

COVID-19 is an illness caused by a coronavirus, a type of virus. COVID-19 was first identified in late 2019 and declared a global pandemic in early 2020. In December 2020, Health Canada authorized the use of two mRNA vaccines, Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY®. These vaccines cause the body to produce protection against infection from COVID-19 using messenger RNA (mRNA) to help make antibodies.

Health staff who do not usually obtain consent for vaccination may be involved in this process to increase the number of Nunavummiut who can be vaccinated at each clinic. These staff will need to be oriented to this new role so that clients are supported to make an informed decision.

The Immunization Manual (https://gov.nu.ca/health/information/manuals-guidelines) provides detailed information on obtaining consent for vaccine administration. The purpose of this document is to provide more specific information on obtaining consent for the Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® vaccines as part of orientation for staff.

Informed Consent:

As indicated in the Immunization Manual:

> *"Immunization providers have an ethical and legal responsibility to ensure that individuals receiving immunizations, or their guardians, are fully informed when making a decision to receive or refuse any vaccines in Nunavut."*

The manual goes on to define the essential criteria for informed consent:

- "Consent must be given willingly and freely without coercion".
- The immunization provider must ensure the vaccine recipient is capable of consenting, or that when required, an appropriate guardian or substitute decision maker is present to give consent.
- Information regarding the risks and benefits of both receiving and not receiving the vaccination should be provided.
- The information should be given in a culturally sensitive way, preferably in the language spoken by the individual receiving the vaccine. Vaccine specific information sheets have been translated to assist in this process.
- An opportunity to ask questions should be provided.
- Minor side effects that occur frequently, any severe adverse effects (such as anaphylaxis), precautions, and contraindications should be discussed.

Age of Consent:

Both the Moderna SPIKEVAX® COVID-19 vaccine and the Pfizer-BioNTech COMIRNATY® vaccine is authorized for use in those 12 years of age and over. In Nunavut the age of majority, the age at which someone can consent for themselves, is 19 years. Mature minors have the necessary capacity to understand the risks and benefits of immunization. *Mature minor status is always decided on a case-by-case basis and requires a judgment call by the immunization provider. A mature minor can override the medical decisions made by his/her parents and can either give consent or refuse immunizations. (NU Immunization Manual Section 3.2.3).* Please refer to the Immunization Manual for further information regarding considerations around informed consent for mature minors.

Documentation:

The COVID-19 Vaccine consent form includes information identifying the client on the front and back of the form. Please ensure that this information is completed on both sides of the form when you are obtaining consent from the client or the parent/guardian. The immunizer documents administration of the vaccine on the back of the form and it is important to have the client's contact information on the same side of the sheet as their signature.

Overview of COVID-19 Infection:

COVID-19 is most commonly spread by an infected person to others through coughing, sneezing, talking, singing or breathing. Someone with COVID-19 may not have any symptoms and not know they have COVID-19, but still be able to infect others.

For most people, symptoms of COVID-19 are similar to other respiratory illnesses like the flu or common cold. A smaller number of people with COVID-19 can develop much more severe symptoms requiring hospitalization and it may result in long term side effects or even death.

Risks and Benefits of <u>Receiving</u> the Vaccine:

Benefits:

The benefit of receiving the vaccine is protection against infection by COVID-19. The Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® vaccines have been evaluated as being both safe and effective in large studies and has been authorized for use by Health Canada following careful review.

- While there is some protection 14 days after the first dose it is not known how long immunity will last after only one dose which means it is important to come back for the second dose.

Risks:

Risks of receiving the vaccine relate to both common side effects and very rare allergic reactions. As indicated in the information sheet:

> The most common reactions that people get after the Moderna and Pfizer-BioNTech vaccines are minor and include:

- Pain, redness or swelling where the needle was given as well as fatigue, headache, muscle pain, joint pain, nausea/vomiting, fever and chills.
- Swelling and tenderness in the underarm of the vaccinated side may also occur.

All of these side effects usually disappear within 1-3 days without treatment. If they do not go away, clients are advised to call the health centre.

Serious adverse events are very rare.

- Myocarditis/pericarditis, Bell's Palsy and Guillan Barre Syndrome are all serious adverse events which have been reported following administration of a COVID-19 mRNA vaccine.
- Serious allergic reactions have also been reported. Symptoms of an allergic reaction include hives (bumps on the skin that are often very itchy), swelling of the face, tongue or throat, or difficulty breathing.
- The clinic staff are prepared to manage an allergic reaction should it occur and will provide immediate medical care if someone develops any of these symptoms. More information on managing anaphylaxis and fainting is in the Practice Guidelines of the Immunization Manual (https://gov.nu.ca/health/information/manuals-guidelines)

Risks and Benefits of Not Receiving the Vaccine:

Benefits:

The benefit of refusing the Moderna SPIKEVAX® or Pfizer-BioNTech COMIRNATY® vaccine is that the client will not be at risk of having side effects from the vaccine and will not have an allergic reaction to the vaccine. The side effects and symptoms or an allergic reaction are identified above.

Risks:

The risk of refusing the vaccine is that the client may be infected by COVID-19. This means the client could develop severe symptoms requiring hospitalization and potentially long-term effects from COVID-19.

A client who refuses the vaccine, and is infected by COVID-19, could also infect members of their household and community, making it more difficult to prevent the spread of the outbreak.

Rationale for Health Questions on Consent Form:

There are several questions on the consent form where the client is asked to respond 'yes' or 'no' for the person receiving the vaccine. This section will provide the rationale on why these questions are asked:

Do you feel sick with a fever today? (If yes please provide details below)

Consideration should be given to postponing vaccination in persons with severe febrile illness. Persons with moderate or severe acute illness should be vaccinated as soon as the acute illness

has improved. Please note, it would be rare for someone who is this sick to be at the vaccination clinic.

Have you had COVID-19? (If yes please indicate when symptoms started below)
You can still receive the vaccine if you've had or think you've had COVID-19 before.

If someone has had COVID-19 it is important to ask when their symptoms started to make sure they are not still infectious. They are no longer infectious 10 days after their symptoms start at which time they can be vaccinated. Vaccination provides additional protection even if someone has had COVID-19.

Are you, or could you be pregnant? *(You will still be offered the vaccine.)*

If someone is, or could be pregnant, they need to know that pregnant people were not included in the initial studies on the Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® vaccines but there is now international real world data to show that COVID-19 vaccines are safe and effective in pregnancy. These clients should be offered the opportunity to discuss vaccination with a nurse or doctor.

If this is your second or third dose, did you have any side effects after a previous dose? (*If yes, please provide details below*.)

If the client had an anaphylactic reaction to the first dose of the Moderna SPIKEVAX® or Pfizer-BioNTech COMIRNATY® vaccine they will need to discuss it with the nurse or doctor at the clinic and they should not be offered any additional doses without further consultation from the Office of the Chief Public Health Officer.

Do you have any problems with your immune system or are you taking any medications that can affect your immune system (e.g., high dose steroids, chemotherapy)? (*If yes, please provide details below.*)

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the vaccine. Nunavut currently recommends a 3rd dose be given to individuals with moderate to severe immunosuppression. Please refer to the relevant COVID-19 immunization protocol for inclusion criteria and further guidance.

Have you received a TB test (TST or IGRA) in the past 4 weeks? (*If yes, when was the TB test: Day / Month / Year).*

A TST or IGRA should not be administered within 28 days of an mRNA COVID-19 vaccine.

There is a theoretical risk that the Moderna SPIKEVAX® or Pfizer-BioNTech COMIRNATY® COVID-19 vaccine may temporarily affect cell-mediated immunity, resulting in false-negative TST or IGRA test results. If tuberculin skin testing or an IGRA test is required, it should be administered and read before immunization or delayed for at least 4 weeks afterwards. Vaccination may take place at any time after all steps of tuberculin skin testing (including reading) have been completed.

However, in cases where an opportunity to perform the TST or IGRA test might be missed, the testing should not be delayed since these are theoretical considerations. In this situation, re-testing, at least 4 weeks post immunization, of individuals with negative results for whom there is high suspicion of TB infection may be prudent to avoid missing cases due to potentially false-negative results.

Please refer to additional guidance provided by the Nunavut Tuberculosis Program.

Do you have a bleeding disorder or are you taking any medications that could affect blood clotting? (*If yes, please provide details below*.)

As with other intramuscular injections, COVID-19 vaccines should be given with caution in individuals with bleeding disorders, such as haemophilia, or individuals currently on anticoagulant therapy, to avoid the risk of haematoma or bad bruise following the injection, and when the potential benefit clearly outweighs the risk of administration. The immunizer will apply pressure to the site for an extra minute to minimize the risk of a bruise.

Have you have had a serious reaction to a vaccine in the past? *(If yes, please provide details below.)*

If someone has had a serious reaction to any vaccine in the past the immunizer needs to be aware of the earlier reaction so they can be prepared, for example, by vaccinating someone lying down if they have fainted before. If someone has previously had an allergic reaction to a vaccine, they should be immunized at the health centre rather than an off-site clinic.

Are you allergic to polyethylene glycol (PEG) or tromethamine which are ingredients in the vaccine?

Two vaccine components have been identified as potentially resulting in a rare allergic reaction: Polyethylene glycol (PEG) can rarely cause allergic reactions and is found in products such as medications, bowel preparation products for colonoscopy, laxatives, cough syrups, cosmetics, skin creams, medical products used on the skin and during operations, toothpaste, contact lenses and contact lens solution. Tromethamine is commonly used as an ingredient in synthetic skincare and cosmetic products as a pH adjuster. <u>NOTE: tromethamine is not an ingredient in the Pfizer-BioNTech COMIRNATY® COVID-19 vaccine.</u>

Have you ever had a severe allergic reaction for which you were prescribed an EpiPen? *(If yes please provide details below.)*

The very limited number of people worldwide who have had a severe allergic reaction to either the Moderna SPIKEVAX® or Pfizer-BioNTech COMIRNATY® vaccines had a history of severe allergic reactions for which they had been prescribed an EpiPen. These people will still be offered the vaccine but clients who say yes to this question can be watched for a longer period of time – 30 minutes post vaccination rather than the usual 15.

Appendix D: Reporting an Adverse Event Following Immunization with COVID-19 Vaccines

Refer to Government of Nunavut's Immunization Manual for more information

The Practice Guidelines in the Immunization Manual provide a comprehensive description of reporting an adverse event following immunization (AEFI). The national AEFI reporting form has been updated and can be found here: https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization.html

Definition of an adverse event following immunization:

An AEFI is any untoward medical occurrence in a vaccinee that follows immunization and may or may not have a causal relationship with the vaccine or the immunization process.

Temporal association alone (onset of event following receipt of vaccine) is not proof of causation.

Recommendations following an adverse event:

A health professional who is aware of an adverse event following immunization occurring must complete an AEFI Report Form. Completed forms should be faxed or emailed to the Regional Communicable Disease Coordinator (RCDC) as soon as possible after the event. A Public Health Officer (PHO), or delegate, will review and work with the team to provide recommendations back to the provider. The Office of the CPHO will ensure all AEFIs are reported to the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS).

Recommendations following adverse event review should be discussed with the client, provided to the client's primary health care provider and documented on the client's chart.

Examples of when to complete an *AEFI Report Form* (more detail in Practice Guidelines):

Example	AEFI Report Form
Events which the client's health care provider considers may be a reason to postpone a future immunization with the same vaccine.	Fill out and send AEFI Report Form to RCDC.
Any unexpected events that are not considered usual side effects of the vaccine.	Fill out and send AEFI Report Form to RCDC
All events managed as anaphylaxis and any allergic events	Fill out and send AEFI Report Form to RCDC
All neurological events including febrile and afebrile convulsions	Fill out and send AEFI Report Form to RCDC
All serious events: life threatening or resulting in death; requiring medical treatment or hospitalization; or resulting in a residual disability.	Fill out and send AEFI Report Form to RCDC *Note: For COVID-19 vaccines, send report if death occurs up to 30 days after vaccination, regardless of cause.*
Local injection site reactions and non-specific systemic reactions (e.g., headache, myalgia) (side effects from the vaccine are found in the COVID-19 Vaccine Information Sheet).	No AEFI Report Form required unless reactions are much more severe than anticipated or last much longer than typically expected.
Vasovagal syncope (fainting)	No AEFI Report Form required
Events which have another obvious cause (e.g., co-existing conditions).	No AEFI Report Form required

Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Appendix E - Transporting and Tracking Vials of Moderna SPIKEVAX® and Pfizer BioNTech COMIRNATY® COVID-19 Vaccines from Regional Distribution Hubs to Vaccination Clinic Sites

Last updated: October 04, 2021

Contents

Background:

The product monograph for both the Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® COVID-19 vaccine(s) recommend that vials be transported in the frozen state due to the unstable nature of the vaccine. In the liquid or thawed state, the vaccine is susceptible to interfacial stresses from being shaken or jostled. If this happens, the vaccine would then be less effective, or perhaps even ineffective, in inducing production of antibodies in the vaccinated person. While vials are normally transported in the frozen state, there are limited circumstances in which refrigerator temperature vaccine would be transported between sites. In addition:

- Vials should never be transported at room temperature between sites.
- Punctured vials should never be transported between sites.
- Liquid (thawed or refrigerator temperature vials) should not be transported by air.
- COVID-19 vaccine will be transported to the Regional Hubs in Iqaluit, Rankin Inlet and Cambridge Bay. These communities will act as regional distribution sites. The vaccines will be further transported to the communities and from the health centre to the vaccination clinic site. At each stage it is important to ensure that the vial(s) are kept at the appropriate temperature. If there is a breach in the cold chain, this failure should be documented using the form: *Incident Report – Vaccine Cold Chain Failure*. For additional information on storage temperatures for the Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® COVID-19 vaccines, please see the respective *COVID-19 Immunization Protocols.*

When vials of COVID-19 vaccine are transported, it is important to:

- Track the numbers of vials through vaccine logs signed by staff from vaccination program.
- Keep vials in original packaging for transport whenever possible.
- Pack the vials well in the transport container with packing materials such as packing peanuts, bubble wrap, blue pads or other materials to minimize any movement.
- Not shake or drop the vaccine.
- Use the TempTale temperature monitoring device (TMD) to monitor cold chain where feasible.
- Do not use dry ice.

The purpose of this document is to provide information on transport of COVID-19 vaccine vials within the territory. For additional information on vaccine storage and handling refer to the Government of Nunavut's *Immunization Manual*.

Description of Vaccine Logs:

COVID-19 Vaccine Vial Shipping Log (Appendix A):

This log is designed to track the number of vials which are transported to Regional Distribution Hubs and from these Regional Hubs to the communities – it tracks where a certain number of vials are going and has space for signatures of the shipper and receiver. This log is self-explanatory and further guidance is not provided in Appendix A.

COVID19 Vaccine Vial Inventory for Community Freezers or Vaccine Fridges Log (Appendix B):

This log is designed to track how many vials are added to and removed from each of the health centre freezers or vaccine fridges, by date and by authorized person. This log is self-explanatory and further guidance is not provided in Appendix B.

COVID19 Vaccine Vial Tracking Log (Appendix C):

This log is designed to capture information on each vial at a vaccination clinic site including: who signed out each vial from the health centre, who the vial was assigned to at the clinic; and the number of doses given as well as the total wastage per vial. Guidance on using Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® COVID-19 Vaccine(s) Vial Tracking Log is provided in Appendix C.

Transport into Territory:

Vaccine will be shipped as per the Federal, Provincial, and Territorial processes to either Rankin Inlet or Iqaluit. Pharmacy staff are responsible for ordering and receiving inventory in compliance with National Operations Centre (NOC) guidelines, including documenting cold chain, and for confirming the orders through the NOC contact.

Transport from Regional Hubs to Community:

Vaccine vials must be maintained at a temperature of **-25°C to -15°C** during transport directly from Regional Hubs to the health centre in a community. This can be achieved by transporting the vials in a portable freezer or in a Crēdo Cube. The Cube(s) is returned to the Regional Pharmacy after the vaccine is placed in the freezer or vaccine fridge in the first community and is never used to transport vials to a subsequent community. Pharmacy technicians pack the vaccine in the freezer or Crēdo Cube for transport to communities.

Planning for transport:

- Review the weekly distribution plan to identify the number of vials to be sent to each of the communities so an appropriate number is sent.
- Ensure each health centre has the appropriate storage equipment, ability, and capacity to store vaccine at the necessary temperature at time of transport.
- Communicate clearly with receiving site on exact time of vaccine delivery to ensure their readiness.
- Plug the portable freezer into a power source to bring to appropriate temperature. Freezer Protocol is provided in Appendix D.
- If a Crēdo Cube is being used, the pharmacy technician at the regional pharmacy hub will ensure the cool packs are placed into the freezer the night before transport.
- Place the packing materials such as packing peanuts, bubble wrap, blue pads or other materials in the freezer (-25°C to -15°C) the night before for conditioning prior to placing in container around vials.
- Initiate the COVID-19 Vaccine Vial Shipping Log to document transport of vaccine vials.

Transporting the vials:

- Use the COVID-19 Vaccine Vial Inventory Log to document the number of vials taken out of the freezer in the Regional Hub.
- Vials are ideally transported in their original packaging and if this is not possible remove from packaging, wrap in bubble wrap and protect from light by placing in an opaque or amber bag.
- Vials are packed securely into freezer or Crēdo Cube with packing material around them so that they do not move at all during transit. Cold packs can also be placed around packing material in case of transportation delays or equipment failure (Appendix D for Freezer Protocol).
- The TempTale TMD is packed with the vials in the container.
- Portable freezers are plugged into a power source on the plane, during drive to health centre (UPC unit) and again in health center.
- Nurse in the community must meet the plane with a UPC to charge the portable freezers during trip to health center. Countertop freezers require a battery pack and cartage company will bring it with freezer to the health center. Freezer must always be plugged in.
- Once the portable freezer is powered on at the health centre - or the Crēdo Cube is opened to access the vials - retrieve the TempTale TMD. This information will assess temperature of the vials during transport. ***DO NOT STOP THE TMD***
- Appendix E provides instructions on downloading information from the TMD and sharing it with pharmacy technicians at regional pharmacy hubs.
- When the vials are moved into the freezer or vaccine fridge at the health centre, the TempTale TMD is placed in the same freezer or fridge to continue recording temperature data.
- Unpack the vaccine and place it carefully into the freezer or vaccine fridge at the health centre when a freezer is not available.
    - Read the display on the TempTale and if it is -2ºC or warmer, visually inspect the vials before placing in freezer. If warmer than 0 or appears to be in a liquid state, place in the fridge, DO NOT refreeze and contact regional pharmacy.
- Check the number of vials received against the Vaccine Shipping Log.
- If the vaccine arrives frozen, with no breach of cold chain, and is placed directly in the freezer it can be stored as follows:
    - Moderna SPIKEVAX®: until the expiry dates indicated on the label, unless otherwise advised by pharmacy. If there has been a breach of cold chain, it must be stored in the vaccine fridge (+2°C to +8°C) and used within 30 days or otherwise as directed by

pharmacy. Thawed vials of vaccine cannot be moved to the next community. Determine if vaccine is thawing by checking TempTale TMD at arrival.

- Pfizer BioNTech COMIRNATY®:
    i. For 14 days at **-25°C to -15°C**. Note that the time used for transport counts against the 14-day limit for frozen storage for Pfizer. If there has been a breach of cold chain it must be stored in the vaccine fridge and used as directed by pharmacy. Thawed vials of vaccine cannot be moved to the next community. Determine if vaccine is thawing by checking TempTale TMD at arrival.
    ii. For 31 days at fridge temperature **+2°C to +8°C**. Note that this is in addition to the 14 days at **-25°C to -15°C.**

- **DO NOT** shake or drop the vaccine
- Use the COVID-19 Vaccine Vial Inventory Log to document the number of vials placed into the freezer or vaccine fridge.

Transporting Vials of COVID-19 Vaccine from one Community to Another

In some circumstances, vials of vaccine will be transported from a Regional Hub to a community, and then on to another community. Only frozen vaccine can be transported by air; this means that if the first community does not have a freezer to store the vaccine, contact the pharmacy team.

A cooler can only be used to transport vaccine to another community when the vials have been stored in the frozen state in the first community; i.e. at a temperature of **-25°C to -15°C** and are placed into the cooler frozen. Frozen vaccine transport by air in a cooler is assumed to be thawing upon arrival and should be placed in a vaccine fridge and used within 31 days.

Planning for transport:

- Pharmacy will review the weekly distribution plan to identify the number of vials to be sent to each of the communities so an appropriate number is sent.
- Pharmacy will work with and oversee Health centre staff to ensure they have the appropriate storage equipment, ability, and capacity to store vaccine at the necessary temperature at time of transport. Pharmacy will communicate clearly with receiving site on exact time of vaccine delivery to ensure their readiness.
- In very rare circumstances a cooler may be used to ship vaccine onwards from a community, but plans are being made to minimize the use of coolers as it is preferable to maintain a temperature of **-25°C to -15°C** throughout transport.
- Prior approval from the pharmacy team to ship the vaccines in a cooler is required.
- If a cooler is being used place the cool packs into the freezer the night before transport.

- Place the packing materials such as packing peanuts, bubble wrap, blue pads or other packing materials in the freezer (-25°C to -15°C) the night before prior to placing in container around vials.
- Initiate the COVID19 Vaccine Vial Shipping Log to document transport of vaccine vials.

Transporting the vials:

- Use the COVID19 Vaccine Vial Inventory Log to document the number of vials taken out of the freezer in the first community.
- Vials are ideally transported in their original packaging and if this is not possible remove from packaging, wrap in bubble wrap and protect from light by placing in an opaque or amber bag.
- Vials are packed securely into freezer or cooler with packing material around them so that they do not move at all during transit. Cold packs can also be placed around packing material in case of transportation delays or equipment failure (Appendix D for Freezer Protocol and Appendix F for details on packing refrigeration pack).
- TempTale TMD must accompany vaccine vials at all times. If some vaccine will be left in a community while the rest is shipped to another community two TempTales will be sent with original shipment.
- Once the cooler is opened to access the vials - retrieve the TempTale TMD. This information will assess temperature of the vials during transport. ***DO NOT STOP THE TMD***
- Appendix E provides instructions on downloading information from the TMD and sharing it with pharmacy technicians at regional pharmacy hubs.
- When the vials are moved into the freezer or vaccine fridge at the health centre, the TempTale TMD is placed in the same freezer or fridge to continue recording temperature data.
- Unpack the vaccine and place it carefully into the freezer or vaccine fridge at the health centre and check the number of vials received against the Vaccine Shipping Log; document vials placed into freezer or fridge with COVID-19 Vaccine Vial Inventory Log.
- If the vaccine arrives frozen, with no breach of cold chain, and is placed directly in the freezer it can be stored as follows:
    - Moderna SPIKEVAX®: until the expiry dates indicated on the label unless otherwise advised by pharmacy. If there has been a breach of cold chain it must be stored in the vaccine fridge and used within 30 days or otherwise as directed by pharmacy. Determine if vaccine is thawing by checking TempTale TMD at arrival.
    - Read the display on the TempTale and if it is -2°C or warmer visually inspect the vials before placing in freezer. If warmer than 0 or appears to be in a liquid state place in the fridge DO NOT refreeze.
    - Pfizer COMIRNATY®:

    - For 14 days. Note that the time used for transport counts against the 14-day limit for frozen storage for Pfizer. If there has been a breach of cold chain, it must be stored in the vaccine fridge and used as directed by pharmacy. Determine if vaccine is thawing by checking TempTale TMD at arrival.
    - For 31 days at fridge temperature **+2°C to +8°C**. Note that this is in addition to the 14 days at **-25°C to -15°C.**
  - Read the display on the TempTale and if it is -2ºC or warmer visually inspect the vials before placing in freezer. If warmer than 0 or appears to be in a liquid state place in the fridge DO NOT refreeze.

- When a cooler is used, vaccine vials are assumed to be thawing upon arrival. **They must be placed in the vaccine fridge, not the freezer, and used according to the appropriate vaccine protocol.**
- **DO NOT** shake or drop the vaccine

Transporting Vials of COVID-19 Vaccine from Health centre to Another Site in the Community for Administration.

This section provides the procedure for transporting both frozen and thawed vials of vaccine from the health centre to a site for administration. Please see the COVID-19 Immunization Protocols for information on thawing frozen vials for Moderna SPIKEVAX® and Pfizer COMIRNATY®.

A frozen vial which is transported to a vaccination site and remains frozen in the cooler at the site can be returned to the health centre fridge not the freezer as it is assumed to be thawing. Thawed vials which are transported to a vaccination site cannot be returned to the health centre as this would mean moving a thawed vial twice. Plans should be made for vaccinating others in the event doses are available off-site to reduce wastage; this could include radio announcements.

Vials should not be transported between sites at *room temperature* and punctured vials should never be transported between sites.

Planning for transport:

When vials are moved from the freezer or vaccine fridge at the health centre to another location for vaccine administration, it is important to plan for transport.

- Notify the person in charge of ordering the vaccine that an identified number of vials will be required for administration of vaccine off-site so the vial(s) will be available in the freezer or vaccine fridge on that day.
- Take the minimum amount of vaccine required to the clinic to prevent any wastage. Document on the COVID-19 Vaccine Inventory Log the number of vials removed from the freezer of fridge.
- If *thawing* vaccine*, w*hen placing vial in a fridge to thaw, please document the date and time for each vial on a separate COVID-19 Vaccine Vial Tracking Log.

- To transport *frozen* vaccine the cooling packs for the refrigeration pack are placed in a separate freezer – not the vaccine freezer - the day before transport.
- To transport *thawed* vaccine the cooling packs for the refrigeration pack are placed into the refrigerator the day before transport.
- Place the packing materials such as packing peanuts, bubble wrap, blue pads or other packing materials in the refrigerator (+2ºC to +8º C) for conditioning the day before.
- Before the vial(s) is to be transported, the cooler is assembled to allow interior to cool (see Appendix F for details on assembling pack).
- *Frozen vial(s)* must stay at **-25°C to -15°C** throughout transportation.
- *Thawed vials* must stay at **+2°C to +8°C** throughout transportation.
- Room temperature is **+8ºC to +25ºC** – vaccine vials should not be transported at room temperature.

Transporting the vial(s):

- Vial(s) will be signed out on the COVID-19 Vaccine Vial Inventory Log and a Vaccine Vial Tracking Log should accompany each vial.
- If transporting *frozen* vaccine, the frozen vial(s) should not be taken out of the freezer and put into the refrigeration pack until the health care team is ready to leave the health centre.
- If transporting *thawed* vaccine, the thawed vial should not be taken out of the refrigerator and put into the refrigeration pack until the health care team is ready to leave the health centre. Care must be taken to ensure the vial does not refreeze during transport - it is important to make sure the vial is not touching the cold pack.
- The manufacturer recommends transporting vials in their box or carton where possible. This may not be realistic as there are too many vials in a box or carton. Each vial should be separately packed in bubble wrap and an opaque or amber bag before being placed into refrigeration pack.
- Be sure to use plenty of padding (packing peanuts, bubble wrap, blue pads or other materials), around vial(s) to reduce movement during transport.
- *Thawed* vials should be kept upright during transport (and storage).
- **The refrigeration cooler with the vial(s) should be secured in the vehicle. The cooler is not to be put on the floor or in the trunk of a car. Avoid sudden movements or braking of the vehicle as much as possible.**
- **Every attempt should be made to carry the cooler without jostling during transport. Be careful not to drop the container with the vial(s).**

Additional notes on home visiting guidance:

In some situations, vaccination is provided during a home visit. Please see Appendix B (*Guidance for Vaccination with COVID-19 Vaccines during a Home Visit)* in the SPIKEVAX® Protocol.

For consideration for future revisions to this guidance (evolving evidence and other guidance from other jurisdictions to be monitored):

- Use of portable freezers in community-to-community vaccine transport.
- Situations in which return of thawed vaccine from an administration site to the health centre might be possible
- The use of TempTale or cold chain markers in cooler at vaccination site.

ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Appendix A COVID19 Vaccine Vial Shipping Log

DATE/ TIME	QUANTITY OF DOSES	QUANTITY OF VIALS	ORIGINATING LOCATION	SHIPPER	SIGNATURE	DESTINATION	RECEIVER	SIGNATURE

Appendix B: COVID19 Vaccine Vial Inventory for Freezers Log

DATE/ TIME	LOCATION	NUMBER OF VIALS ADDED	BALANCE OF VIALS	NAME (PRINT)	SIGNATURE

DATE/ TIME	LOCATION	NUMBER OF VIALS REMOVED	BALANCE OF VIALS	NAME (PRINT)	SIGNATURE

Appendix C: Moderna SPIKEVAX® and Pfizer BioNTech COMIRNATY® Vial Tracking Logs

Moderna SPIKEVAX® vaccine usage and wastage needs to be carefully tracked and reported back to the Health Protection Unit in order to track COVID-19 vaccination coverage rates in the territory. Please note that this is in addition to documenting vaccine doses given in Meditech within 24 (at most 36) hours of administration.

Steps to follow:

1) Front line providers will use the *NU Covid-19 Vaccination - Mandatory Vaccine Vial Tracking Sheet* for every vial of Moderna SPIKEVAX® or Pfizer COMIRNATY® vaccine used and send in to RCDC with a copy to CDClabs@gov.nu.ca as soon as possible after clinic is completed (no later than same day). Please see Log next page.

2) RCDC will review the tracking sheets received daily for practice issues, compile the sheets into the *COVID 19 Vaccine Vial Usage Summary* spreadsheet and send into CDClabs@gov.nu.ca as soon as complete (no later than same day).

3) If completed vial tracking sheets are not received from the clinic by the end of the day, RCDC will follow-up with the clinic lead to request that they be sent as soon as possible.

4) Surge Response CD Specialist will file both the vial tracking sheets and vial usage summaries on the shared drive.

5) Pandemic response team gathers data and creates a regular report. Data from vial tracking sheets and summaries may be cross-checked against COVID-19 immunization coverage data pulled from Meditech before being reported to the Public Health Agency of Canada.

Please see next page for Moderna SPIKEVAX® and Pfizer COMIRNATY® Vial Tracking Logs (full-page pdf also available, image provided here is just for reference).

NU COVID-19 VACCINATION - MANDATORY VACCINE VIAL TRACKING - MODERNA SPIKEVAX®

Date:	
Community:	
Mass vaccination clinic Y/N	
Date Vaccine arrived in the Community	
Freezer available in community Y/N	
Freezer Accompanying Vaccinators Y / N	
(Held at -15 to -25 degrees until ready for use)	

Please scan in batches and email form as soon as feasible to RCDC, copying cdclabs@gov.nu.ca, every few hours (no later than same day). More detail on roles noted below. Date sent to RCDC and CDClabs@gov.nu.ca: ______________

Emails
For Kitikmeot region: fdigout@gov.nu.ca
For Kivalliq region: kivalliq_covid19@gov.nu.ca
For Qikiqtaaluq region: covid19_qikiqtaalukrcdc@gov.nu.ca

LOT#	ASSIGNED VIAL #							
EXPIRY	Name of Person Signed out to:							
	Name of Person Assigned to**:							
Removed from Freezer:	time (24hr)							
Thawed in refridgerator (+2°C to +8°C) Stable for 30 days	Y / N							
	start time							
	end time							
	date to discard by (30days)							
Thawed at Room Temperature (+8°C to +25°C)	Y / N							
	start time							
	end time							
	time to puncture by (24 hours)							
Vial Punctured (Vaccine stable for a **CUMULATIVE** total of 24 hrs at room temp. Time of puncture does not reset the time)	Y / N							
	start time							
	end time (must discard)							
		DOSE		STAFF INITIAL		DOSE		STAFF INITIAL
		0.25 ml	0.5 ml			0.25 ml	0.5 ml	
Initials of clients given dose from vial (optional)	1				12			
	2				13			
	3				14			
	4				15			
	5				16			
	6				17			
	7				18			
	8				19			
	9				20			
	10				21			
	11				22			
Doses Used from Vial:	Administered							
	Wasted*							
	Wastage code							
	Waste/use comments							
Vial used for home visiting	Y / N							
Signature of vaccine floater or clinical lead								

*Note: wasted or discarded refers to all unused doses (timed out, no one left to vaccinate without transporting vial). Important to capture and
** If same person assigned to for all vials, can draw a line through to the end to indicate this
Please follow green and red sticker process as outlined by pharmacy team.
Empty vials - keep and store. Send count of empty vials at end of day. Vials can be discarded when this tracking sheet matched, signed off, and sent to RCDC and CDCLabs@gov.nu.ca

Roles: RCDC to review forms, flag any concerns, and follow up with clinic as appropriate
Person monitoring CDCLabs will store a copy in a secured folder on shared drive

Wastage Codes	
AA	Damaged vial/vaccine
BB	Refridgerated > 30 days
CC	Room Temp > 24 hours
DD	Punctured > 24 hours (Cumulative)
EE	Not enough in Vial (i.e. < 0.5ml)

Additional Notes / Comments / Observations on storage/transport/use:

Nunavut COVID-19 Mass Immunization Clinic Materials
Last updated:October 29, 2021

NU COVID-19 Mass Vaccination Materials
Department of Health, Government of Nunavut (may be adapted outside Nunavut as long as source acknowledged)

NU COVID-19 VACCINATION - MANDATORY VACCINE VIAL TRACKING - PFIZER COMIRNATY®

Date:	
Community:	
Mass vaccination clinic Y/N	
Date Vaccine arrived in the Community	
Freezer available in community Y/N	
Freezer Accompanying Vaccinators Y / N	
(Held at -15 to -25 degrees until ready for use)	

Please scan in batches and email form as soon as feasible to RCDC, copying cdclabs@gov.nu.ca, every few hours (no later than same day). More detail on roles noted below. Date sent to RCDC and CDClabs@gov.nu.ca: ________________

Emails
For Kitikmeot region: fdigout@gov.nu.ca
For Kivalliq region: kivalliq_covid19@gov.nu.ca
For Qikiqtaaluq region: covid19_qikiqtaalukrcdc@gov.nu.ca

LOT#		ASSIGNED VIAL #							
EXPIRY		Name of Person Signed out to:							
		Name of Person Assigned to**:							
Removed from Freezer:		time (24hr)							
Thawed in refrigerator (+2°C to +8°C) (Takes ~3 hours to thaw) Stable for 31 days undiluted		Y / N							
		start time							
		end time							
		date to discard by (31 days)							
Thawed at Room Temperature (+8°C to +25°C) (Takes 30 minutes to thaw) Stable for 2 hours undiluted		Y / N							
		start time							
		end time							
		time to puncture by (2 hours)							
Vial Punctured (Vaccine stable for 6 hours ONLY)		Y / N							
		start time							
		end time (must discard)							
Initials of clients given dose from vial (optional)		1							
		2							
		3							
		4							
		5							
		6							
		7							
Doses Used from Vial: (usual 6 per vial)		Administered							
		Wasted*							
		Wastage code							
		Waste/use comments							
Vial used for home visiting		Y / N							
Signature of vaccine floater or clinical lead									

*Note: wasted or discarded refers to all unused doses (timed out, no one left to vaccinate without transporting vial). Important to capture
** If same person assigned to for all vials, can draw a line through to the end to indicate this
Please follow green and red sticker process as outlined by pharmacy team.
Empty vials-keep and store. Send count of empty vials at end of day. Vials can be discarded when this tracking sheet matched, signed off, and sent to RCDC and CDCLbas@gov.nu.ca

Roles: RCDC to review forms, flag any concerns, and follow up with clinic as appropriate
Person monitoring CDCLabs will store a copy in a secured folder on shared drive

Wastage Codes	
AA	Damaged vial/vaccine
BB	Refridgerated > 31 days
CC	Room Temp > 2 hours
DD	Punctured > 6 hours (Cumulative)
EE	Not enough in Vial

Additional Notes / Comments / Observations on storage/transport/use:

Nunavut COVID-19 Mass Immunization Clinic Materials
Last updated:October 29, 2021

NU COVID-19 Mass Vaccination Materials
Department of Health, Government of Nunavut (may be adapted outside Nunavut as long as source acknowledged)

Appendix D Freezer Protocol

1. Immediately plug in the freezer upon arriving to the health center.
2. Once the freezer is powered on, open the freezer, and retrieve the TempTale Temperature Monitoring Device (TMD).
3. See separate instructions for downloading information from the TMD. ***DO NOT STOP THE TMD* (Appendix E).**
4. When emailing the TMD data, please re-name the PDF document with community you are sending the data from and the date.
5. Place the TMD back in the freezer to continue recording temperature data.
6. Send data daily during Mass Vaccination Clinics (MVC) and twice weekly if no MVC.
7. Any shipments that arrive in a cooler or Crēdo cube should be placed in the **fridge** with the datalogger. Continue to send the data at the same intervals from the TMD regardless of whether the necessary storage is fridge or freezer. (Daily during MVC and twice weekly if no MVC).
8. Crēdo cubes and dataloggers are to be returned to the originating regional pharmacy once no longer needed to be reused.
9. Unpack the vaccine by snipping the zip ties. Keep the bubble wrap as it will be required to pack the vaccine for transportation to the next community. Additional zip ties have been provided.
10. Take the minimum amount of vaccine required out of the freezer to prevent any wastage.
11. **DO NOT** shake or drop the vaccine!
12. To continue to the next community, make sure that any unused frozen vaccine remains in the freezer.
13. Use the packing supplies to secure the vaccine for transportation.
14. Please use packing tape to secure the door of the freezer for flight.
15. Do not unplug the freezer until it is time to bring the freezer to the aircraft.
16. Use a UPC to power the freezer for the trip from the health centre to the plane and from the plane to the health centre.
17. Plug in the freezer into the aircraft power supply.
18. *Repeat steps 1-5 upon arriving at the health centre.

Michael Gauvin (Iqaluit) mgauvin@gov.nu.ca (867)975-8600 Ext. 6352, pager (867)979-7646 pager #126.

Amanda Arsenault (Rankin Inlet) aarsenault@gov.nu.ca (867)645-8334, On-call phone # (867)645-7978.

ᐋᓐᓂᐊᖃᖅᑐᓕᕆᔨᒃᑯᑦ
Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Appendix E - **Instructions for use of TempTale** Temperature Monitoring Device

If any issues or concerns, please contact technicians at the regional pharmacy hubs:

Michael Gauvin (Iqaluit) mgauvin@gov.nu.ca 1-867-8600 ext 2306, pager 1-867-979-7646 pager # 126

Amanda Arsenault (Rankin Inlet) aarsenault@gov.nu.ca 1-867-645-8334 On call phone 645-7978

PLEASE EXECUTE THE FOLLOWING STEPS:

1. Upon receipt, remove TempTale® from shipping container. "DO NOT STOP THE DEVICE"

2. Plug reader into a computer's USB port and send the files to the Regional Pharmacy Technician. (**Michael Gauvin** mgauvin@gov.nu.ca for the **Qikiqtaaluk** region and **Amanda Arsenault** aarsenault@gov.nu.ca for the **Kivalliq** and **Kitikmeot** regions.). These should be sent daily during mass vaccination clinics, any major transport, any temperature excursions, and at least every 72 hours. **Any major temperature excursions should be reported immediately to CPHO/DCPHO.**

3. Check TempTale® LCD display for alarm status:
   a) **If X** icon appears,
      i. Segregate product within appropriate temperature and do not use until disposition is provided from your Regional Pharmacy Technician.
      ii. Reference instructions below for alarming TempTale®.

   b) **If** icon appears, the product has stayed within the temperature and can be accepted. Return TempTale® to shipping freezer.

4. Place product in proper storage conditions according to product label.

No Alarm

Alarm

DOWNLOAD AND RETURN INSTRUCTIONS - For Alarmed TempTales® only if X icon appears

1. The device is a USB TempTale®, plug the USB connector of the TempTale® directly into a USB port on the computer.

2. Search and open either the TT4USBMA or TTULTRAUSB drive (removable storage) on the computer. **Call QGH at (867)975-8600 Ext 6352 or Kivalliq Health centre at (867)645-8334 if further instructions are needed.**

3. Select .TTV or .TTX file, right click on the file, and place the mouse over 'Rename' and change the name of the file to your community name and the date. Then place the mouse over 'Send To' and select 'Mail Recipient.' Email .TTV or .TTX file to Michael Gauvin at mgauvin@gov.nu.ca for Qikiqtaaluk region or Amanda Arsenault at aarsenault@gov.nu.ca for Kivalliq and Kitikmeot region.

Note: It will not be possible to open and view the data in the .TTV or .TTX file but the PDF file is readable.

Department of Health
Munaqhiliqiyitkut
Ministère de la Santé

Appendix F: Immunization Manual 3.1.7 Maintaining Cold Chain during Transport

[Note that this guidance is adapted from the Nunavut Immunization Manual and is copied here for convenience. For updates, it is best to check the Immunization Manual.]

The following items are essential for ensuring that cold chain is maintained during transport and when conducting clinics outside of the health centre.

Hard-sided plastic insulated container

Refrigerator-conditioned cold packs

Newer Styrofoam cooler with walls at least 2 inches thick

Vaccines should be packed in layers to prevent shifting of the contents during transport. Be sure to place an insulating barrier between the refrigerated or frozen packs and the vaccines to prevent accidental freezing.

Container for transport

Vaccines should be transported in insulated containers. Soft-sided coolers, thin-walled coolers, and banged-up Styrofoam containers should not be used. Please note that Vaccines are double-boxed during the winter months (Oct.1 to May 31)

Cooling Packs

There are two main types of cooling packs: refrigerator-conditioned (refrigerated at +2°C to +8°C) and frozen packs available for packing vaccines. The use of these packs for transporting vaccines will depend on the ambient temperature, the amount and type of vaccine, and the size of the container.

Frozen Packs

Insulating Barrier/Filler Materials and the Vaccine

Packing peanuts

Bubble wrap

Blue pads



Pack vaccines in their original packaging on top of the barrier. Do not remove vaccine vials from individual boxes – if multiple vials are in a single box the vial required for the home visit will need to be removed. Be sure to fill any spaces between vaccine boxes with crumpled paper or other filler to prevent shifting of contents in the insulated container.

Temperature Monitor

Warm/cold markers Min/max thermometer

Use a properly placed min/max thermometer or cold chain monitor near the vaccine. The temperature- monitoring device should be placed in the middle of the vaccines and should not come in contact with the refrigerated or frozen packs.

References:

1. Adapted from Nova Scotia Immunization Manual, by the Government of Nova Scotia, 2008. Adapted with permission.
2. Public Health Agency of Canada (2007). National Vaccine Storage and Handling Guidelines for Immunization Providers [PDF version]. Retrieved from http://www.phac- aspc.gc.ca/publicat/2007/nvshglp-ldemv/pdf/nvshglp-ldemv-eng.pdf.

Appendix F - COVID-19 Vaccine Clinic Client Screening Questionnaire

Have you been experiencing any of the following symptoms?		
• Fever higher than 38C or subjective (self identified) fever	Yes ☐	No ☐
• New or worsening cough	Yes ☐	No ☐
• New or worsening shortness of breath/breathing difficulties	Yes ☐	No ☐
• Sore throat	Yes ☐	No ☐
• Runny nose/nasal congestion	Yes ☐	No ☐
• Vomiting and or diarrhea	Yes ☐	No ☐
• New symptoms that are unusual to you – muscle aches, headache, fatigue, loss of sense of smell or taste, loss of appetite	Yes ☐	No ☐
Have you been advised to isolate related to COVID-19 at this time?	Yes ☐	No ☐
Have you been in close contact, in the last 14 days, with someone that is confirmed to have COVID-19?	Yes ☐	No ☐
Have you returned from a community in Nunavut with cases of COVID-19 cases in the last 14 days and are required to isolate?*	Yes ☐	No ☐
Have you returned from out-of-territory travel in the last 14 days and are required to isolate?**	Yes ☐	No ☐

If no to all questions → Proceed through vaccination process.

If yes to any question → Nurse floater role assesses and determines if can proceed with vaccination. If not, take down name and contact information and arrangement appointment at health centre. At that appointment, will need to assess need for COVID-19 testing as well as to consider providing vaccination. Should be arranged for as soon as is feasible and can be done in groups in order to maximize vial usage (e.g. group of individuals booked).

*Answering "yes" to this question is not necessarily an exclusion unless the client is required to isolate. Please refer to current Public Health orders relating to in-territory travel and isolation requirements.

**Answering yes to this question is not necessarily an exclusion unless the client is required to isolate. Generally travellers who have spent 14 days in a hub prior to entering the territory are not required to isolate when they return to their home community.

Appendix G COVID-19 Vaccine Protocol

COVID-19 Mass Vaccination Clinic Booking Script

1. "*Hello. I'm calling to offer you (or your child) the COVID-19 vaccine."*

2. Book appointment as per health centre or mass vaccination clinic processes.
   - Please ensure you have checked both name and date of birth and review spelling on Meditech.
   - Appointments should be booked in Meditech whenever possible.

3. Ask *"Is there anybody else we should book an appointment for right now who also wants to have the vaccine, such as others in your household?"*

4. Book those appointments as per health centre or mass vaccination clinic processes, same as above.

5. Book appointment. Tell the caller "***I have some information for you about your vaccine***":
   - ✓ *Your (or your child's) appointment is on* (DATE: _____) at (Time: _____)
   - ✓ *The vaccination clinic will be located at*: (PLACE: _____)
   - ✓ *Masks are required at the COVID-19 vaccination clinic.*
   - ✓ *If you can, try to only bring people who have an appointment to get a vaccination to the clinic. We are trying to not have crowds at the place of the immunizations.*
   - ✓ *If you have symptoms of COVID-19 (e.g. cough, fever, difficulty breathing) please do not come to the immunization clinic. Call the Health Centre and talk with a nurse.*
   - ✓ *People should wear T-shirts or sleeveless shirts to make it easy to get their vaccine.*

IF PERSON SAYS NO TO VACCINE, YOU COULD SAY: "*We are recommending that all adults and children over 12 get the COVID-19 vaccine. The vaccine is the best protection we have against getting sick from COVID-19. Would you like to talk with a nurse about your concerns with the vaccine?"*

COVID-19 Booster Vaccine Doses

Please read this information sheet carefully and ensure you have a chance to ask a health care provider your questions before receiving the vaccine.

Why the need for booster doses?

To date, COVID-19 vaccines have been shown to maintain high vaccine effectiveness against serious illness, hospitalization, and death from COVID-19 in most populations. However, evidence is emerging that vaccine effectiveness against asymptomatic infection and mild COVID-19 disease may decrease with time, and that currently authorized COVID-19 vaccines may be less effective against the highly transmissible Delta variant (B.1.617.2).

A decrease in effectiveness could contribute to increased spread of infection. Therefore, an additional or booster dose may be needed to ensure adequate protection in some populations.

When should a booster dose be given?

Evidence from clinical trials suggests that booster doses of mRNA vaccines should be given six months after the primary series to provide additional protection from COVID-19. This means six months from your second dose of an mRNA vaccine.

What is the difference between a booster dose and an additional dose in a primary series (i.e. for those immunocompromised)?

For most people, 2 doses of an authorized COVID-19 vaccine (i.e. Moderna SPIKEVAX® or Pfizer BioNTech COMIRNATY®) is sufficient to complete a primary vaccine series. Real world evidence suggests that compared to the general population, individuals who are moderately to severely immunocompromised have lower immune responses to COVID-19 vaccines. Therefore, these individuals are immunized with a primary series of three doses of either Moderna SPIKEVAX® or Pfizer BioNTech COMIRNATY®.

The purpose of a booster dose is to restore protection that may have decreased over time to a level that is no longer deemed sufficient in individuals who initially responded adequately to a complete primary vaccine series.

At present time, who should be offered booster doses in Nunavut?

In Nunavut at present time, all eligible individuals over the age of 12 can receive a booster dose of either Moderna SPIKEVAX® or Pfizer BioNTech COMIRNATY®. Please talk to your health care provider if you have any questions about eligibility.

Do I need to receive the same mRNA vaccine as my booster dose?

It has been recommended that either Moderna SPIKEVAX® or Pfizer BioNTech COMIRNATY® can be offered as a booster dose, regardless of which vaccine was given in the primary series.

Will COVID-19 vaccines become an annual immunization similarly to influenza vaccine?

It can take years of post-market use to determine the optimal intervals and dose number needed for a complete primary series to sustain long-term protection. Over time, it may be learned that a short 2-dose (or 3-dose for immunocompromised) primary series, with a booster of at least 6 months after the second dose, can result in durable protection. Evidence on this subject is evolving.

Will the booster dose become a requirement to travel without isolating?

At this time, there are no plans to make this a requirement for territorial rules.

ᓄᕙᒡᔭᐊᕐᓇᖅ-19-ᒧᑦ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᖅ ᑲᐳᑎᑦ

ᐅᑯᐊ ᑎᑎᕋᖅᓯᒪᔪᑦ ᐅᖃᓕᒫᑦᑎᐊᕐᓗᒋᑦ ᐱᕕᒃᓴᖃᓕᕈᕕᑦ ᐃᓗᐊᖕᓴᐃᔾᔪᑦ ᐊᐱᖅᓱᑎᐊᕐᓂᐊᖅᐳᑎᑦ ᑲᐱᔭᐅᓚᐅᙱᓐᓂᕐᓂ.

ᖃᓄᐃᒻᒪ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᕐᒥ ᑲᐱᔭᐅᔭᓇᐊᖅᑲᕐᐸ?

ᐅᑦᑐᒥᒧᑦ, ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ ᑲᐳᑎᑦ ᐊᑑᑎᖃᒻᒪᓇᒃᓯᒪᔪᑦ ᐋᓐᓂᐊᕋᓗᙱᑦ, ᐋᓐᓂᐊᕖᙲᐊᕐᑕᐅᓂᙱᑦ, ᑐᕐᑯᒧᑦᑐ ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ ᐊᒥᓱᓂ. ᑭᓯᐊᓂᓕ, ᖃᐅᔨᔭᐅᕙᑦᓕᐊᓕᕐᑐᖅ ᑲᐳᑎ ᐊᑑᑎᖃᕐᓂᖓ ᖃᓂᒪᖅᑰᔾᔩᕐᑐᒧ ᐋᓐᓂᐊᒧ ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᖄᕐᔭᒃᑐᓄᑦᑐ ᒥᒃᓴᕚᑦᓕᑐᐃᓐᓇᓇᐊᖅᑲᙵᑕ ᖃᖓᐅᓕᖅᐸᕐ, ᒫᓇ ᐊᕐᒋᖅᑕᐅᓯᒪᔪᑦ ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ ᐊᑑᑎᖃᓗᐊᙱᑐᐃᓐᓇᓇᐊᓕᑦ ᓯᐊᒻᒪᔭᑦᑐᒻᒪᓇᖕᒧᑦ ᓄᕙᒡᔭᐊᕐᓇᖅ ᐊᔾᔨᒋᙱᑕᖕᒐᓂ (Delta variant (B.1.617.2)).

ᐊᑑᑎᖃᕈᓐᓃᕐᐸᓪᓕᐊᓂᖕᒐ ᓯᐊᒻᒪᒍᑕᐅᒃᑲᓂᕈᓐᓇᕐᑐᖅ ᖃᓂᒻᒪᓯᖕᒥᑦ. ᑕᐃᒪᐃᒻᒪᑦ, ᑲᐱᔭᐅᒃᑲᓂᕐᓂᖅ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᕐᔫᓐᓃᑦ ᑲᐳᑎᒥ ᐱᔭᓇᐊᖅᑐᐃᓐᓇᓇᐊᓕᑦ ᓴᐳᑎᔭᐅᓯᒪᑦᑎᐊᕐᑯᑦᑐᒋᑦ ᐃᓚᖏᑦ ᐃᓄᐃᑦ.

ᖃᖓᓕ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᕐᒧᑦ ᑲᐱᔭᐅᔭᓇᐊᖅᑲᕐᐸ?

ᖃᐅᔨᔭᐅᓯᒪᓕᖅᑐᑦ ᐋᓐᓂᐊᕕᓐᓂ ᖃᐅᔨᓴᕐᓂᒃᑯᑦ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓃᑦ ᑲᐳᑎᑦ mRNA–ᓂᑦ ᑲᐱᔭᐅᑦᑐᐊᖅᑐᑦ ᑕᖅᑭᑦ 6 ᓯᕗᓪᓕᑦ ᑮᒍᓂᐊᓂ ᓴᐳᑎᓯᒪᒃᑲᓐᓂᕐᑯᑦᑐᒋᑦ ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ. ᑕᐃᒪᓕ ᑕᖅᑭᑦ 6 ᐊᐃᑉᐸᖓᓂᑲᐱᔭᐅᕆᓂᒃᓯᒪᓕᕈᕕᑦ mRNA ᑲᐳᑎᒧᑦ.

ᑭᓯᓇᑦᓕ ᐊᔾᔩᙶᕐᒥᒪᑕ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᖅ ᑲᐳᑦ ᐊᒪᓗ ᑲᐳᑎᒃᑲᓐᓂ ᓯᕗᓪᓕᕐᓂᑦ (ᓲᕐᓗ ᑕᐃᒃᑯᐊ ᑎᒥᖏᑦ ᐅᓇᑕᐅᑎᖅᑖᑎᐊᙱᑦᑐᑦ)?

ᐊᒥᓱᓄ ᐃᓄᖕᓄᑦ, ᒪᕐᕉᒃ ᑲᐳᑦ ᐊᖏᖅᑕᐅᓯᒪᔪᓂ ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ ᑲᐳᑎ (ᓲᕐᓗ Moderna SPIKEVAX® ᐅᕝᕙᓘᓐᓃᑦ Pfizer BioNTech COMIRNATY®) ᓇᒻᒪᒃᑐᖅ ᐱᐊᓂᖕᓂᐊᕐᓗᒋᑦ ᑕᒪᐃᓐᓂᒃ ᑲᐳᑎᑦ. ᐱᓪᓚᑦᑖᒥ ᓴᖅᑭᓯᒪᔪᑦ ᐃᓄᑐᐃᓐᓇᕐᓂ, ᐃᓄᐃᑦ ᑎᒥᖏᑎᒍ ᐅᓇᑕᐅᑎᖃᕈᐊᙱᑦᑐᑦ ᐅᓇᑕᐅᑎᖅᙱᑦᑐᓪᓘᓐᓃᑦ ᐊᑦᑎᖕᓂᖅᓴᓂ ᑎᒥᖓ ᐅᓇᑕᐅᑎᖃᕈᐊᙱᑦᑐᑦ ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ. ᑕᐃᒪᐃᓐᓂᖓᓄᑦ, ᐅᑯᐊ ᐃᓄᐃᑦ ᑲᐱᔭᐅᓯᒪᔪᑦ ᐱᖓᓱᐃᕐᔫᑎᒃ ᐅᑯᓂᖓ Moderna SPIKEVAX® ᐅᕝᕙᓘᓐᓃᑦ Pfizer BioNTech COMIRNATY®.

ᐱᔾᔪᑕᐅᔪᕐᓕ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᖕᒧᑦ ᑲᐳᑎ ᓴᐳᑎᔭᐅᒃᑲᓐᓂᕐᑯᓗᒍ ᐊᑐᕈᓐᓃᕐᐸᓪᓕᕐᓂᖓᓄ ᖃᖓᐅᓕᕐᑎᓪᓗᒍ ᓈᒻᒪᒍᓐᓃᕐᓗᓂ ᐃᓄᖕᒧᑦ ᖃᓄᐃᙱᑎᑦᑎᐊᓚᐅᕐᑐᒧᑦ ᑕᒪᐃᓐᓄᑦ ᑲᐱᔭᐅᓪᓗᓂ.

ᒫᓇᐅᔪᖅ, ᑭᓇ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᕐᒥᑦ ᑲᐱᔭᐅᓪᓗᐊᕐᐸ ᓄᓇᕗᒻᒥᑦ?

ᓄᓇᕗᒻᒥᑦ, ᒫᓇᐅᔪᖅ, ᑲᐱᔭᐅᔪᓐᓇᕐᑐᓕᒫᑦ ᐅᑭᐅᓕᑦ 12 ᐅᖓᑖᓄ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᕐᒥᑦ ᑲᐱᔭᐅᔪᓐᓇᕐᑐᑦ ᓇᓕᐊᓐᓂᑐᐃᓐᓇ Moderna SPIKEVAX® ᐅᕝᕙᓘᓐᓃᑦ Pfizer BioNTech COMIRNATY®. ᐅᖃᖃᑎᖃᕐᓗᑎᒃ ᐋᓐᓂᐊᓯᐅᑎᔅᓯᓐᓂᑦ ᐊᐱᖅᑯᑎᒃᓴᖃᕈᕕᑦ ᐱᔪᓐᓇᕐᒪᙶᕐᐱᑦ.

ᐊᔾᔨᒃᑲᓐᓂᐊᓂ mRNA ᑲᐱᔭᐅᔭᓇᐊᖅᑲᕐᐳᖓ ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᕐᒥ?

ᐊᑐᕐᑯᔭᐅᔪᑦ ᓇᓕᐊᓐᓂ Moderna SPIKEVAX® ᐅᕝᕙᓘᓐᓃᑦ Pfizer BioNTech COMIRNATY® ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᐅᔪᓐᓇᕐᑐᑦ, ᐃᓱᒪᒋᓇᒋ ᓇᓕᐊᓐᓄᑦ ᓯᕗᓪᓖᕐᓄ ᑲᐱᔭᐅᓚᐅᕋᓗᐊᕐᑎᓪᓗᑎᑦ.

ᓄᕙᒡᔭᐊᕐᓇᖅ-19–ᒧᑦ ᑲᐳᑎᑦ ᐊᕐᕌᒍᑕᒫᖅ ᑲᐱᔭᐅᔭᓇᐊᖅᑲᕐᓇᔾᔭᕐᐸ ᓲᕐᓗ ᓄᕙᒃᔭᐃᒃᑯᑎᑐᐃᓐᓇᕐᓄᑦ ᑲᐳᑎᑐᕐ?

ᐊᕐᕌᒍᒐᓴᖕᓄᑦ ᑭᖑᓂᐊᓂ ᐊᑐᕐᑕᐅᓗᓂ ᖃᐅᔨᔭᐅᓇᓱᒃᑐᓂ ᖃᓄᖅ ᐊᑯᓂᐅᑎᒋᖃᑦᑕᕋᔭᕐᒪᖔᑦ ᖃᓄᑎᒋᓗ ᑲᐱᔭᐅᖃᑦᑕᓇᐊᖅᒪᖔᑦ ᐃᓯᓕᓐᓇᓱᒃᑐᒋᑦ ᑕᒪᐃᓐᓂᒃ ᐊᑯᓂᐅᔪᒧᑦ ᓴᐳᑎᓯᒪᓂᐊᕐᓗᓂ. ᖃᖓᓕᕐᐸᑦ, ᐃᓕᑕᐅᑐᐃᓐᓇᓇᐊᓕᒃ ᕿᓚᒻᒥᐅᔪᓄ 2-ᑲᐳᑎᑦ (3-ᑲᐳᑎᓪᓘᓐᓃᑦ ᑎᒥᒥᒍᑦ ᐅᓇᑕᐅᑎᖅᑦᑎᐊᙱᑦᑐᓄᑦ) ᓯᕗᓪᓕᕐᓂᑦ, ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᖅᑲᕐᓗᓂ ᑕᖅᑭᑦ 6 ᑮᒍᓂᐊᒍ ᐊᐃᑉᐸᖓᓂ ᑲᐱᔭᐅᓚᐅᕐᑎᓪᓗᒍ, ᓴᐳᔾᔨᑦᑎᐊᕐᓯᒪᔪᓐᓇᕐᑐᖅ. ᖃᐅᔨᔭᐅᕙᓪᓕᐊᔪᑦ ᑕᒪᑐᒧᖓ ᐊᓯᔾᔨᖅᐸᓪᓕᐊᔪᑦ.

ᐋᓐᓂᐊᓕᓅᒃᑯᑎᒃᑲᓐᓂᖅ ᑲᐳᑎᒧ ᑲᐱᔭᐅᓯᒪᔭᓇᐊᖅᑲᕐᓇᕐᓂᐊᓕᕐᐸ ᐊᐅᓪᓚᕐᓂᐊᕐᓗᓂ ᐊᓂᑦᑕᐃᓕᓚᐅᙱᓪᓗᓂ?

ᒫᓇᐅᔪᖅ, ᐸᖓᓇᒃᓯᒪᔪᖅᑲᙱᑦᑐᖅ ᑕᐃᒪᐃᑦᑕᓇᐊᖅᑲᕐᓗᓂ ᓄᓇᕗᒻᒥᑦ ᒪᓕᒋᐊᓕᖕᓂᑦ.

COVID-19 Ikayuutighaq Pingahuat Kapuut

Taiguaqlugu una kangiqhidjut titiraq taiguatiaqlugu apiripkaqlutillu apirhuutigharnik munaqhinun kapuqhiqtinatit.

Huuq ihariagiyat ikayuutighaq kapuqhidjut?

Ublumimun, qalagyuarnirmun COVID-19 kapuutit tautungnaqtut anginirhakkut kapuqhiqhimayut ihuarutigiyaat aanniaqtailinirmun aghut, aanniavingmungarnirmun, huinirmunlu qalagyuarnirmin COVID-19 tamavyaini inugiangnirni. Kihimi, naunaiyautit nuivalialiqtut kapuutip ihuarnirit mihingnautiqangitut aanniarunmik mikiyuqlug qalagyuarniq COVID-19 aanniarut mighiyuuminiaqtuq qakugu, tadja tamna qalagyuarnirmun COVID-19 kapuut mikiyumik ihualuanginiaqtuq uvanga anginirhaanun hiamitiqtup Delta variantmin (B.1.617.2).

Mighiyuumirutait ihuarnirit pidjutauniaqtut angikliyuumiqniaqtuq hiamitirnira aanniarutip. Taimaali, ilaliutihimayut ikayuutighat kapuutit ihariagiyauyut ihuaqtumik aanniaqtailidjutighat ilanginun inugiangnirnun.

Qakugu ikayuutighakkut kapuutinik kapuqhirniaqqat?

Tautungnaqtut uuktuutini ihumagiyauyut tapkua ikayuutighat kapuutit haffuminga mRNAmik kapuqhiqtughat siksini tatqiqhiutini kinguani hivulirmik kapuqhirnirmik tunihiyaangini ilaliutihimayunik aanniaqtailidjutighanik qalagyuarnirmun COVID-19. Una naunaiyauta siksini tatqiqhiutini tuglirmik kapuqhirunmik haffuminga mRNA kapuutaanik.

Hunauva aalaudjutaa qitqani ikayuutit kapuutit ilaliutihimayuqlu kapuqhirut hivuani (imaa tapkua aannialaqitailidjutiqaqtut)?

Tamavyainun inungnun, tugliq kapuqhirut angiqtauhimayumi qalagyuarnirmun COVID-19 kapuutaa (imaa. Moderna SPIKEVAX® unaluuniin Pfizer BioNTech COMIRNATY®) naamaktuq initirutaa hivuani kapuutit kapuqhirutait. Nunaqyuami tautungnaqtut ihumagiyauyut tapkua aadjiliurutigiblugit inugiangnirit, atautit kitut aanniaqtailidjutiqaqtut aannialaqitaaqtut kiudjutaanun qalagyuarnirup COVID-19 kapuutaanin. Taimaali, hapkua atautit kapuqhiqpaktut pingauiqturlugit haffuminga Moderna SPIKEVAXmik® unaluuniin Pfizer BioNTech COMIRNATY®.

Pidjutaa ikayuutighaq kapuut ihuaqhaidjutauyuq aanniaqtailinirmun mighiyuumiqtuq qakunguraangat aktilaanganun hakuiqpaliabluni atautinun kitut kiudjutigiyaat ihuaqtumik kapuqhimayunun.

Tadja, kitut tuniyauyughat ikayuutighamik kapuunmik Nunavunmi?

Nunavunmi tadja, tamaita kapuqhiqtaaqtut atautit ukiuqaqtut avatqumayumik tualut kapuqhiqtaaqtut ikayuutighanik haffuminga Moderna SPIKEVAXmik® Pfizer BioNTech COMIRNATYmikluuniin®. Uqaqatigilugit munaqhitkut quyaginaq apirhuutighaqaruvin kapuqhirnikkut.

Piyariaqaqaik mRNA kapuutaanik ikayuutighamik kapuunik?

Pitquyauyuq tapkua Moderna SPIKEVAXmik® Pfizer BioNTech COMIRNATYmikluuniin® kapuqhiqtaaqtut ikayuutighamik, kituugaluaqtilugu kapuut kapuqhirutit hivuani.

Qalagyuarnirmun COVID-19 kapuutit ukiutigut kapuqhiqpalirniaqqat fluuqtailinikkut kapuutaanik?

Ukiut amigainiaqtut atungnirit ihumaliurutigilugit auladjutait kapuqhirnikullu qaffiuniit ihariagiyauyut iniriangani hivuanin pihimalugu hivituyumik-aanniaqtailidjut. Qakugunguqqat, iliturivauniaqtuq tapkua naituq malruk-kapuqhirutik (unaluuniin pingahuuyut aannialaqitailidjutiqaqtut) hivuani, ikayuutikkut kapuqhiutit imaa siksini tatqiqhiutini kinguani tuglirup kuapuqhirutip, pidjutauniaqtuq aanniaqtailinirmun. Tautungnarnirit haffumunga aulahimaaqtut.

Ukua ikayuutit kapuqhirutit piyariaqarniaqqat tingmitinani avaliingaaqtitauhimaitumik?

Tadja, upalungaiyautiqangituq una piyariarutaanun aviktuqhimayumi maligahanun.

Dose de rappel d'un vaccin contre la COVID-19

Veuillez lire attentivement la présente fiche d'information et poser vos questions à un professionnel de la santé avant de recevoir un vaccin.

À quoi servent les doses de rappel?

À l'heure actuelle, les vaccins contre la COVID-19 maintiennent une haute efficacité contre les infections graves, les hospitalisations et les décès associés à la maladie dans la majorité des populations. Toutefois, des données émergentes indiquent que l'efficacité vaccinale contre les infections asymptomatiques et les infections légères à la COVID-19 pourrait baisser au fil du temps, et que les vaccins actuellement autorisés pourraient offrir une protection inférieure contre le très contagieux variant Delta (B.1.617.2).

Un déclin de l'efficacité pourrait faire augmenter la transmission de la maladie. Ainsi, une dose supplémentaire ou une dose de rappel pourrait être requise pour assurer une bonne protection chez certaines populations.

À quel moment la dose de rappel devrait-elle être administrée?

Les données d'essais cliniques indiquent que la dose de rappel d'un vaccin à ARNm devrait être administrée six mois après la série primaire afin de fournir une protection accrue contre la COVID-19. Cela signifie qu'elle devrait être administrée six mois après la réception de la deuxième dose d'un vaccin à ARNm.

Quelle est la différence entre une dose de rappel et une dose supplémentaire dans une série primaire (administrée aux personnes immunodéprimées)?

Pour la plupart des gens, deux doses d'un vaccin autorisé contre la COVID-19 (SPIKEVAX® de Moderna ou COMIRNATY® de Pfizer-BioNTech) sont suffisantes pour compléter une série vaccinale primaire. Des données issues de la vie réelle indiquent que, comparativement à la population générale, les personnes modérément ou gravement immunodéprimées présentent une réponse immunitaire inférieure aux vaccins contre la COVID-19. Ainsi, ces personnes reçoivent une série primaire de trois doses du vaccin SPIKEVAX® de Moderna ou du vaccin COMIRNATY® de Pfizer-BioNTech.

Le but de la dose de rappel est de restaurer la protection, qui pourrait avoir baissé avec le temps jusqu'à un niveau jugé insuffisant, chez les personnes qui avaient initialement présenté une bonne réponse à la série vaccinale primaire.

À l'heure actuelle, qui devrait recevoir une dose de rappel au Nunavut?

Présentement au Nunavut, toutes les personnes admissibles de plus de 12 ans peuvent recevoir une dose de rappel du vaccin SPIKEVAX® de Moderna ou du vaccin COMIRNATY® de Pfizer-BioNTech. Veuillez consulter un professionnel de la santé si vous avez des questions au sujet de l'admissibilité.

Dois-je recevoir le même vaccin à ARNm pour la dose de rappel?

Selon les recommandations actuelles, les vaccins SPIKEVAX® (Moderna) et COMIRNATY® (Pfizer-BioNTech) peuvent être administrés comme doses de rappel, quel que soit le vaccin reçu à la série primaire.

Les vaccins contre la COVID-19 seront-ils administrés chaque année comme c'est le cas pour le vaccin contre la grippe?

Des années d'utilisation post commercialisation peuvent être nécessaires pour déterminer le nombre de doses requises et les intervalles optimaux entre celles-ci pour que la série primaire procure une protection à long terme. Au fil du temps, on pourrait constater qu'une courte série primaire de deux doses (ou de trois doses pour les personnes immunodéprimées), suivie d'une dose de rappel au moins six mois après la deuxième dose, pourrait procurer une protection durable. Les connaissances sur le sujet continuent d'évoluer.

La dose de rappel deviendra-t-elle une exigence pour voyager sans période d'isolement?

Pour l'instant, il n'est pas prévu que l'administration d'une dose de rappel fasse partie des règlements territoriaux.